1 Evolution of long-term vaccine induced and hybrid immunity in healthcare

2 workers after different COVID-19 vaccination regimens: a longitudinal

3 observational cohort study

4

4		
5 6 7	Shona Alexa Meara	a C. Moore ¹ *, Barbara Kronsteiner ^{2,3} *, Stephanie Longet ^{4,5} *, Sandra Adele ^{*2,3} , ndra S. Deeks ^{2,6} , Chang Liu ^{5,24} , Wanwisa Dejnirattisai ^{5,7} , Laura Silva Reyes ⁸ , Naomi don ⁹ , Sian Faustini ¹⁰ , Salv Al-Taei ¹⁰ , Tom Tipton ^{4,5} , Luisa M Hering ¹ , Adrienn Angyal ¹¹
, 8	Rebe	cca Brown ¹¹ Alexander R Nicols ¹² Susan L Dobson ¹ Pivada Supasa ⁵ Aekkachai
9	Tuekr	prakhon ⁵ Andrew Cross ¹³ Jessica K Tverman ¹² Hailey Hornsby ¹¹ Irina Grouneva ¹¹
10	Mega	n Plowright ^{9,11} . Peijun Zhang ¹¹ . Thomas A.H. Newman ^{9,11} . Jeremv M. Nell ¹⁴ . Privanka
11	Abrah	am ^{2,3} , Mohammad Ali ^{2,3} , Tom Malone ² , Isabel Neale ^{2,3} , Eloise Phillips ² , Joseph D.
12	Wilso	n ^{2, 6,15} , Sam M. Murray ² , Martha Zewdie ² , Adrian Shields ^{10,16} , Emily C. Horner ¹⁷ , Lucy
13	H. Bo	oth ¹⁷ , Lizzie Stafford ⁵ , Sagida Bibi ⁸ , Daniel G. Wootton ^{1,13,18} , Alexander J. Mentzer ^{5,6} ,
14	Christ	opher P. Conlon ^{3,5} , Katie Jeffery ^{6,19} , Philippa C. Matthews ^{2,20,21,22} , Andrew J.
15	Pollar	d ^{5,8,23} , Anthony Brown ² , Sarah L. Rowland-Jones ^{9,11} , Juthathip Mongkolsapaya ^{5,24} ,
16	Rebe	cca P. Payne ¹² , Christina Dold ^{8,23} , Teresa Lambe ^{8,24} , James E.D. Thaventhiran ¹⁷ , Gavin
17	Screa	ton ^{5,24} , Eleanor Barnes ^{2,6,23,25} , Susan Hopkins ^{26,27,28} , Victoria Hall ^{26,28} , Christopher JA
18	Dunca	an ^{12,14} †, Alex Richter ^{10,16} †, Miles Carroll ^{4,5} †, , Thushan I. de Silva ^{9,11} †, Paul
19	Klene	rman ^{2,6,23,25} †^, Susanna Dunachie ^{2,3,6,29} †, Lance Turtle ^{1,13,} †^ on behalf of the PITCH
20	Conse	ortium+
21		
22	1.	NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute
23	0	of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
24	2.	Peter Medawar Building for Pathogen Research, Nuffield Dept. of Clinical Medicine,
25	0	University of Oxford, UK
26 27	3.	University of Oxford, UK
28	4.	Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford,
29		UK
30	5.	Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of
31		Oxford, UK
32	6.	Oxford University Hospitals NHS Foundation Trust, Oxford, UK
33	7.	Division of Emerging Infectious Disease, Faculty of Medicine Siriraj Hospital, Mahidol
34		University, Bangkok, Thailand
35	8.	Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
36	9.	Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
37	10.	Institute for Immunology and Immunotherapy, College of Medical and Dental
38		Science, University of Birmingham, UK
39	11.	Department of Infection, Immunity and Cardiovascular Disease, University of
40	40	Sheffield, UK
41 42	12.	I ranslational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, UK
43	13.	Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
44	14.	Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS
45		Foundation Trust, UK
46	15.	Oxford University Medical School, Medical Sciences Division, University of Oxford,
47		Oxford, UK

- 48 16. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 49 17. MRC Toxicology Unit, University of Cambridge, Cambridge, UK
- 50 18. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK
- 51 19. Radcliffe Department of Medicine, University of Oxford, UK
- 52 20. The Francis Crick Institute, London, UK
- 53 21. Division of Infection and Immunity, University College London, London, UK
- 54 22. Department of Infectious Diseases, University College London Hospital NHS
 55 Foundation Trust, London, UK
- 56 23. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- 57 24. Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of
 58 Oxford, Oxford, UK
- 59 25. Translational Gastroenterology Unit, University of Oxford, UK
- 60 26. UK Health Security Agency, London, UK
- 61 27. Faculty of Medicine, Department of Infectious Disease, Imperial College London, UK
- 82 28. NIHR Health Protection Research Unit in Healthcare Associated Infection and
 Antimicrobial Resistance, University of Oxford, UK
- 64 29. Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
- 65
- 66 *These authors contributed equally
- 67 †Senior Author
- 68 ^Corresponding authors:
- 69 Lance Turtle, Ronald Ross Building, Department of Clinical Infection, Microbiology and
- 70 Immunology, University of Liverpool, 8 West Derby Street, L69 7BE.
- 71 lance.turtle@liverpool.ac.uk
- 72 Paul Klenerman, Peter Medawar Building for Pathogen Research, University of Oxford,
- 73 Oxford OX1 3SY, UK. paul.klenerman@ndm.ox.ac.uk
- 74

75 Secondary Author List

- Hibatullah Abuelgasim, Emily Adland, Zahra Ahmed, Hossain Delowar Akther, Ahmed
 Alhussni, Ali Amini, M. Azim Ansari, Rachel Anslow, Carolina V. Arancibia-Cárcamo, Ana
- Alhussni, Ali Amini, M. Azim Ansari, Rachel Anslow, Carolina V. Arancibia-Cárcamo, Ana
 Atti, James Austin, Angela Bailey, Martin Bayley, Alice Bridges-Webb, Helen Brown, Holly
- 79 Caborn, Jeremy Chalk, Meera Chand, Anu Chawla, Senthil Chinnakannan, Elizabeth
- 80 Clutterbuck, Debbie Cross, Joseph Cutteridge, Sophie Davies, Catherine de Lara, Lucy
- 81 Denly, Ben Diffey, Stavros Dimitriadis, Timothy Donnison, Thomas M Drake, Maeva Dupont,
- 82 Elena Efstathiou, David Eyre, Alex Fairman, Sarah Foulkes, John Frater, Siobhan Gardiner,
- Javier Gilbert-Jarmillo, Philip Goulder, Jessica Gregory, Carl-Philipp Hackstein, Sophie
- Hambleton, Muzlifah Haniffa, Helen Hanson, Kate Harrington, Jenny Haworth, Carole Hays,
- Jennifer Holmes, Fatima Mariam Ilyas, Jasmin Islam, Anni Jämsén, Chris Jones, Geraldine
- Jones, Mwila Kasanyinga, Sinead Kelly, Maqsood Khan, Jon Kilby, Rosemary Kirk, Michael
- 87 L. Knight, Allan Lawrie, Lian Lee, Lauren Lett, Katy Lillie, Nicholas Lim, Alison Lye,
- 88 Spyridoula Marinou, Chloe Matthewman, Jessica McNeill, Gracie Mead, Hema Mehta,
- Haniffa Muzlifah, Christopher Norman, Denise O'Donnell, Ane Ogbe, Juyeon Park, Brendan
- 90 A. I. Payne, Gareth Platt, Sonia Poolan, Nicholas Provine, Narayan Ramamurthy, Nichola
- 91 Robinson, Leigh Romaniuk, Patpong Rongkard, Ayoub Saei, Oliver L. Sampson, Donal
- 92 Skelly, Jarmila S. Spegarova, Gareth Stephens, Emily Stephenson, Rachel Stimpson,
- 93 Krishanthi Subramaniam, Chloe Tanner, Lydia J. Taylor, Chitra Tejpal, Sarah Thomas, Neal
- 94 Townsend, Simon Travis, Nicola Trewick, Stephanie Tucker, Helena Turton, Zara Valiji,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 95 Adam Watson, Lisa Watson, Esme Weeks, Rachel Whitham, Jayne Willson, Barbara
- 96 Wilson, Robert Wilson, Steven Wood, Huiyuan Xiao, Amira A. T. Zawia

97

It is made available under a CC-BY-NC-ND 4.0 International license .

98 Abstract

99

100 Both infection and vaccination, alone or in combination, generate antibody and T cell 101 responses against SARS-CoV-2. However, the maintenance of such responses – 102 and hence protection from disease - requires careful characterisation. In a large 103 prospective study of UK healthcare workers (Protective immunity from T cells in 104 Healthcare workers (PITCH), within the larger SARS-CoV-2 immunity & reinfection 105 evaluation (SIREN) study) we previously observed that prior infection impacted 106 strongly on subsequent cellular and humoral immunity induced after long and short 107 dosing intervals of BNT162b2 (Pfizer/BioNTech) vaccination. Here, we report longer 108 follow up of 684 HCWs in this cohort over 6-9 months following two doses of BNT162b2 or AZD1222 (Oxford/AstraZeneca) vaccination and up to 6 months 109 110 following a subsequent mRNA booster vaccination. We make three observations: 111 Firstly, the dynamics of humoral and cellular responses differ; binding and neutralising antibodies declined whereas T and memory B cell responses were 112 113 maintained after the second vaccine dose. Secondly, vaccine boosting restored IgG 114 levels, broadened neutralising activity against variants of concern including omicron 115 BA.1, BA.2 and BA.5, and boosted T cell responses above the 6 month level post 116 dose 2. Thirdly, prior infection maintained its impact driving larger as well as broader T cell responses compared with never-infected people - a feature maintained until 6 117 118 months after the third dose. In conclusion, broadly cross-reactive T cell responses are well maintained over time – especially in those with combined vaccine and 119 120 infection-induced immunity ("hybrid" immunity) – and may contribute to continued 121 protection against severe disease. 122 123

124

It is made available under a CC-BY-NC-ND 4.0 International license .

125 INTRODUCTION

126 As vaccines have been deployed to tackle the SARS-CoV-2 pandemic, crucial 127 questions have emerged regarding long-term maintenance of protective immunity 128 against disease. The appearance of viral variants leading to successive waves of 129 infection has clearly shown the limits of vaccine protection against infection (UK 130 Health Security Agency, 2022). Despite this, vaccine protection against severe 131 disease has been well maintained across the recent delta (Tartof et al., 2021) and 132 omicron BA.1 (Andrews et al., 2022) waves. To understand the underlying immune 133 responses that determine these population-level observations, large-scale studies of 134 individuals with high exposure to SARS-CoV-2, such as health care workers 135 (HCWs), can provide valuable insights as has been demonstrated by the SARS-136 CoV-2 immunity & reinfection evaluation (SIREN) study in the UK (Hall et al., 2022; 137 Hall et al., 2021a; Hall et al., 2021b). Protective Immunity from T Cells in Healthcare 138 workers (PITCH), a study aligned closely with SIREN, is focused on the longitudinal 139 analysis of antiviral T and B cell responses after infection and/or vaccination with 140 BNT162b2 (Pfizer/BioNTech) or AZD1222 (Oxford/AstraZeneca). PITCH has already 141 provided data indicating that the extended interval vaccine regimen for BNT162b2 142 mRNA vaccine deployed in the UK was associated with enhanced antibody and 143 CD4⁺ T cell helper responses (Payne et al., 2021a). All immune responses were 144 strongly enhanced by prior SARS-CoV-2 infection.

145

146 The long-term impacts of prior exposure, vaccine regimen and vaccine type have not 147 been fully defined, especially at the level of T cell responses. Characterising the 148 response to vaccines and infections in healthy people is essential to determine future 149 vaccination policies, while identification of vulnerable non-responders can inform 150 additional interventions such as extra booster doses of vaccine and/or monoclonal 151 antibody therapies. Correlations with protection from infection at a population level 152 have been observed for binding (Earle et al., 2021; Gilbert et al., 2022) and 153 neutralising antibodies (Addetia et al.; Feng et al., 2021; Gilbert et al., 2022; Khoury 154 et al., 2021; Moore et al., 2021). The role of other, non-neutralising antibody 155 functions, such as antibody-dependent NK cell activity, antibody-dependent 156 phagocytosis or complement deposition, requires further investigation (Ewer et al., 157 2021; Kaplonek et al., 2022a; Tomic et al., 2022). However, monitoring of SARS-158 CoV-2 specific T cell immunity is also essential, as T cell defence is potentially a key 159 explanation for lower case hospitalisation and mortality for the omicron variant 160 compared with earlier variants (Nyberg et al., 2022), despite omicron's high mortality 161 in unvaccinated populations (Mefsin et al., 2022). T cells are a cornerstone of 162 antiviral defence, orchestrating the immune response including cytotoxic activity 163 against virally infected cells and optimising production of antibodies from B cells 164 (Sette and Crotty, 2021). Macague (McMahan et al., 2021) and human (Kedzierska 165 and Thomas, 2022; Molodtsov et al., 2022; Rydyznski Moderbacher et al., 2020) 166 studies support this key role for T cells in protection against the severe effects of 167 SARS-CoV-2 infection, potentially alongside functional antibody properties beyond 168 neutralisation (Bartsch Yannic et al.; Kaplonek et al., 2022b). In some cases, cross-

It is made available under a CC-BY-NC-ND 4.0 International license .

- 169 reactive T cells are associated with protection against infection in exposed
- 170 seronegative groups (Kundu et al., 2022). There is also evidence of SARS-CoV-2
- 171 specific cell responses in highly exposed HCW without seroconversion (Ogbe et al.,
- 172 2021), and expansion of pre-existing RNA-polymerase-specific T cells in
- 173 seronegative SARS-CoV-2 infection (Swadling et al., 2022).
- 174

There is a body of emerging data on the waning of antibody responses, especially 175 176 after the shorter dose interval regimen for BNT162b2 (Goldberg et al., 2021; Naaber 177 et al., 2021). Waning of antibody is associated with loss of protection against 178 infection (Hall et al., 2022; Wei et al., 2022b), whereas protection against severe 179 disease is relatively well maintained (Andrews et al., 2022; Carazo et al., 2022; Lin et 180 al., 2022; Rosenberg et al., 2021; Tartof et al., 2021; UK Health Security Agency, 181 2022). T cell responses to spike protein post vaccination do not correlate strongly 182 with binding or neutralising antibody responses (Payne et al., 2021a). Importantly, 183 whilst antibodies generated in response to vaccination neutralise omicron much less 184 well than the ancestral strain (Dejnirattisai et al., 2022; Schmidt et al., 2021), the T 185 cell response to SARS-CoV-2 is minimally impacted by mutations in the alpha, beta, 186 gamma and delta variants of concern (Payne et al., 2021a; Skelly et al., 2021), and 187 75-85% preserved against the omicron BA.1 variant (De Marco et al., 2022; Gao et 188 al., 2022; GeurtsvanKessel Corine et al., 2022; Keeton et al., 2022; Liu et al., 2022; 189 Madelon et al., 2022; Tarke et al., 2022). Given that at this point in the pandemic, 190 public health decisions are increasingly being made around limiting severe disease 191 rather than preventing milder infections in the community, having robust data at 192 scale that indicates the trajectory of the T cell responses after different vaccine 193 regimens is of increasing value. The impact of subsequent vaccine dosing on T and 194 B cell responses is additionally a key focus in such decision making. 195 196 We previously observed higher anti-spike binding, higher neutralising antibody

197 responses and lower spike-specific T cell magnitude but increased IL2 production 198 one month after second dose when BNT162b2 was delivered with a longer dosing 199 interval (median 10 weeks) compared to the licensed shorter (3-4 weeks) interval 200 (Payne et al., 2021a). This pattern was reproduced in an elderly population (Parry et 201 al., 2022), and the antibody findings have been confirmed in the larger SIREN cohort 202 (Otter et al., 2022). Evidence of improved vaccine effectiveness with a longer dose 203 interval was reported in a study of two Canadian provinces (Skowronski et al., 2022). 204 205 In the study presented here, our objective was to explore the characteristics of 206 adaptive and humoral immunity following two and three vaccine doses, to consider

207 the longer-term impacts of regimen variation, vaccine type (including the Oxford-AZ 208 ChadOx1-based vaccine) and infection over time. We observed the long-term impact 209 of prior infection even after two doses of vaccine, which is consistent with protection 210 documented in SIREN (Hall et al., 2022). We saw no decline in T cell responses over 211 time regardless of vaccine regimen — this contrasts with waning of both binding and 212 neutralising antibody (NAb) titres, which remained strongest and broadest in the long

It is made available under a CC-BY-NC-ND 4.0 International license .

213 interval BNT162b2 group. The third dose of vaccine boosted binding antibody

214 responses such that differences seen between vaccine regimens after only two

215 doses were reduced as were differences associated with prior infection. Overall, the

216 data indicate a stable pool of T cell memory is induced and maintained across

- 217 vaccine types/regimens, consistent with the sustained impact of vaccination with or
- 218 without prior infection in protection against severe disease.
- 219

220 RESULTS

221

222 Participants vaccinated with a primary course and a booster dose of COVID vaccine 223 We studied 684 participants who had been vaccinated with a primary course of 224 COVID-19 vaccine between 9th December 2020 and 23rd May 2021 (Table 1 and 225 Figure 1). In total, 592 participants received a primary course of BNT162b2 vaccine 226 (Pfizer), of whom 84 participants received the second dose of BNT162b2 vaccine 227 after a short (3-5 week, median 24 days) interval, and 508 participants received the 228 second dose of BNT162b2 vaccine after an extended (6-17 week, median 71 days) 229 interval (Payne et al., 2021a). 92 participants received a primary course of AZD1222 230 vaccine administered with an interval of 7-23 weeks (median 74 days). The median age of all participants was 43 (range 22-77), and 73.8% of participants were female, 231 232 reflecting the demographic of healthcare workers in the UK and consistent with our 233 previous reports, and the wider SIREN cohort.

234

235 Symptomatic infection and asymptomatic anti-nucleocapsid (N) seroconversion were 236 common during the study period

237 During follow up of this cohort (May 2021 to March 2022), some participants became 238 infected during the SARS-CoV-2 waves of delta and omicron BA.1 or BA.2 (Table 1). 239 33 participants developed symptomatic COVID-19 confirmed by positive SARS-CoV-240 2 PCR assay. A further 49 participants had evidence of asymptomatic infection 241 between one and 6 months after the second vaccine, reflected by SARS-CoV-2 N 242 antibody seroconversion detected in the 6 month samples. After accounting for those 243 infections, half the cohort (342 participants) met the definition of infection-naïve at 244 the time of the third vaccination. In addition, 11 participants of 21 followed up to 6 245 months post third dose became infected with omicron variants. 246 247 We measured T cell responses 6 months after the second vaccine dose and found 248 that participants infected between one and 6-months after the second dose had 249 similar T cell responses to those infected prior to their first vaccine dose (Figure S2). 250 Spike IgG, measured by MesoScale Discovery (MSD), was lower in those infected

251 during the study compared with those infected before vaccination, but was higher

than infection naïve participants. Therefore, in this report, participants with natural

infection at any point were analysed together as a "hybrid immunity" group,

regardless of when the infection occurred in relation to vaccine doses.

255

Six months post second vaccination, T cell IFNy ELISpot responses are greatest
 following BNT162b2 short dose interval at six months and are augmented in
 participants with hybrid immunity

259 In infection-naïve participants, at 6 months post vaccine dose 2, there was no 260 significant difference in the T cell response by IFNy ELISpot assay between the 261 three primary vaccine groups, although there was a trend towards higher T cell 262 responses in those who received BNT162b2 vaccine with a short interval (median 3 263 weeks) than those groups who were vaccinated with a BNT162b2 long interval 264 (median 10 weeks), or the group vaccinated with AZD1222 (Figure 2A). This 265 difference was significant for the BNT162b2 short and long interval groups one 266 month after the second dose (Payne et al., 2021a). Spike-specific T cell responses 6 months after the second vaccination were considerably greater in all groups (105 267 SFU/10⁶ PBMC, IQR 48 – 240) than the historical median responses we observed 268 269 using the same assay in this cohort pre-vaccination in 2020 (Tomic et al., 2022) 6 months after wave 1 infection (44 SFU/10⁶ PBMC, IQR 1-107). 270

271

For anti-spike binding antibody responses, levels were higher for BNT162b2

recipients than AZD1222 recipients irrespective of the dosing interval (Figure 2B). A
similar pattern was apparent for RBD antibody (Figure 2C). As was observed at one
month post second dose, T cell and antibody responses were greater in magnitude
in those who were previously infected at any point before the 6-month post second
dose sample was collected (Figure 2A-C). T cell responses against M and N were,
as expected, higher in those with hybrid immunity, and correlated with N antibody
levels (Figure 2D).

280

After a booster (third) vaccine, IFNγ ELISpot T cell responses are equivalent in all
 groups irrespective of primary vaccine regimen

283 Over the 6-month period following the second vaccine dose, T cell IFNy responses 284 were well maintained, with a modest fall which did not reach statistical significance, 285 and, overall, were boosted significantly after the third dose in both naïve and hybrid 286 immune participants (Figure 3A). This apparent boost was accounted for by the largest group, the BNT162b2 long interval group (Supplementary Figure S3A, D and 287 288 G), whilst the other, smaller, groups did not achieve statistical significance. These 289 responses were well maintained for 6 months following the third dose, with no 290 significant change in T cell response between 1 and 6 months post third dose, 291 although fewer hybrid immune participants were tested at this timepoint (Figure 3A). 292 One month after the third vaccine dose, participants receiving all three vaccine 293 regimens had equivalent T cell IFNy responses (Figure 3D). The post dose 3 294 boosting effect did not generate T cell responses any higher than those measured 28 295 days post dose 2, but responses were higher than those measured 6 months post 296 dose 2 value. Thus, all groups derived a detectable benefit on the T cell response 297 from the third vaccine dose.

298

It is made available under a CC-BY-NC-ND 4.0 International license .

Infection leads to boosting of IFNγ ELISpot T cell responses following all vaccine regimens

301 Spike-specific T cell responses were higher in those with hybrid immunity compared 302 with infection naïve. This was the case for both BNT162b2 vaccinated groups 303 (Supplementary Figure S3A and D) but was not the case in the AZD1222 group 304 (Supplementary Figure S3G). T cell responses were still higher one month post dose 305 3 in those who had been previously infected with SARS-CoV-2 (Figure 3A). However, by 6 months post dose 3 the spike-specific T cell response in naïve and 306 307 hybrid immune participants was equivalent (Figure 3A). M and N responses were 308 higher in BNT162b2 vaccinated participants with hybrid immunity, but this difference 309 was not seen in the AZD1222 group. Between one month post dose 2 and one 310 month post dose 3, even in the group who did not seroconvert to N, we detected a 311 rise in the T cell response to M and N in the BNT162b2 long interval naïve group (the 312 largest group), which became significant one month after the third dose 313 (Supplementary Figure S4D), and appeared to increase still further at the 6 month 314 time point (although this was not significant). Given that T cell responses are more 315 sustained than antibody responses, this presumably reflects people who became 316 asymptomatically infected but whose subsequent samples were taken after waning 317 of the N antibody response. We saw no such change in the AZD1222 group 318 (Supplementary Figure S4G).

319

320 Humoral responses wane quickly but are boosted by third dose vaccination 321 After the second vaccine dose, binding antibody responses decreased sharply. The 322 median SARS-CoV-2 spike IgG titre (MSD) decreased 5.6-fold in naive vaccine 323 recipients and 3.3-fold in the hybrid immunity group by 6 months (Figure 3B). 324 Participants who received the different vaccine regimens followed similar patterns 325 (Figure S3B, E and H). Naïve participants who received AZD1222 had lower spike 326 antibody titres post second dose than those receiving BNT162b2 regimens, but 327 these titres were then boosted 25-fold by the third (BNT162b2 mRNA) vaccine dose 328 (Figure S3H). One month after the third dose, spike antibody IgG binding levels 329 increased back to similar levels to those measured one month post dose 2 (Figure 330 3B). By 6 months after the third dose, the rate of waning was less than after the 331 second dose, and was less in the naïve group than in the hybrid immune group. The 332 naïve group waned by 1.4-fold between one and 6 months after the third dose, which 333 was not significant, compared with 5.8-fold after the second dose. The hybrid 334 immune group waned 1.9-fold between one and 6 months post dose 3, compared 335 with 3.2-fold in the equivalent period after the second dose. The reduction was 336 significant for the hybrid group, and brought it down to a level equivalent to that of 337 the naïve group by 6 months post dose 3.

338

After the third dose, there was no significant difference in the magnitude of the spike binding IgG response between vaccine regimens (Figure 3E). Overall, a subtle (1.4fold) but significant increase in spike IgG remained between previously infected and naïve participants one month after the third dose (Figure 3B). The IgG levels

343 measured post dose 3 were significantly greater than those measured post dose 2 in 344 naïve participants, but those with hybrid immunity did not derive additional benefit 345 from the levels one month post dose 2, although there was a substantial boost over 346 the 6 month post dose 2 level in this group. The RBD binding response followed the 347 same pattern as the total spike response (Supplementary Figure S4B, E, H) and N 348 antibody titres were unchanged by vaccination in the hybrid immune group 349 (Supplementary Figure S4C, F, I). However, some of the naïve participants did show 350 rises in N antibody between one and 6 months post third dose. This time period 351 corresponded to the very large wave of omicron BA.1 in the UK, and likely 352 represents subclinical infection in some of our participants.

353

354 Memory B cell responses were measured by IgG ELISpot in a subset of 106 355 participants (Figure 3C, Supplementary Figure S3C, F and I). Six months after the 356 second dose, memory B cell frequencies were similar between naïve and hybrid 357 immunity group, and these responses were preserved, with no statistically significant 358 difference from one month post second dose. In the whole dataset, memory B cell 359 responses were not impacted by the third vaccine dose, though there was a 360 significant increase in the BNT162b2 long interval and AZD1222 groups in both 361 naïve participants, (Supplementary Figure S3F and I), and in the BNT162b2 long 362 interval participants with hybrid immunity (Supplementary Figure S3F). Unlike the T 363 cell IFNy response, where there was still an advantage in those previously infected, 364 there was no increase in the memory B cell response in those previously infected in any group (Figure 3C and F). 365

366

These data indicate that although antibody levels decline between the second and third vaccine doses, T and B cell responses are well maintained across this period. Hybrid immunity conferred an advantage on the magnitude of the T cell and antibody response at all timepoints, including after the third vaccine dose, but did not for the B cell response. The third vaccine dose boosted immunity back to previous levels, or greater, with a tendency to even out any earlier differences between two-dose vaccine regimens.

374

375 Our cohort was mostly female, but the BNT162b2 short interval group contained 376 significantly more male participants (30 of 84, 40.5%, p=0.006, Chi squared test, 377 Table 1). We did not detect any significant differences in responses between the three vaccine regimens, but to ensure that there was no potential for the imbalance 378 379 in male participants to influence this, we ran regression models to investigate the 380 influence of age, sex, previous SARS-CoV-2 infection and vaccine regimen on log₁₀ 381 transformed spike-specific IgG and T cell responses (see Supplementary Table 382 regression analysis). Multivariable models indicated that previous infection was 383 independently associated with both IgG and T cell responses, but that male sex was 384 inversely associated with T cell responses (Supplementary Tables 1A and E). 385 Multivariable models were used to explore the effect of sex within each vaccine 386 regimen group, for IgG and T cell responses. Sex had no effect on IgG responses in

387 all three vaccine groups (Supplementary Tables 1B, C and D). Responses were 388 negatively associated with age and associated with previous infection in the 389 BNT162b2 long interval group. For T cell responses, previous infection was 390 associated with T cell responses in the BNT162b2 groups, and male sex was 391 negatively associated with T cell responses only in the AZD1222 group (Table 2C). 392 Therefore, the male imbalance did not affect the measurement of responses in the 393 BNT162b2 short interval group. Although we found evidence that T cell responses to 394 a booster mRNA vaccine are weaker in men who have received a primary course of 395 AZD1222, this must be viewed with caution as it is based on only 24 participants. 396 397 Polyfunctional T cell responses are detectable six months after vaccination, with 398 enhancement in individuals with hybrid immunity 399 T cell responses measured by intracellular cytokine staining (ICS) were lower at 6 400 months post second dose in AZD1222 vaccinated participants compared with 401 BNT162b2 recipients (Figure 4A), in line with the ELISpot findings. T cell function 402 was similar between the two BNT162b2 groups, and there was less IL-2 and TNF 403 made by the AZD1222 group (Figure 4A). These differences evened out in the hybrid 404 immunity group. CD8⁺ T cells made a substantial fraction of the IFNy, at least half on 405 average (Figure 4B), with a trend to more in the AZD1222 group, as known for chimpanzee adenovirus vectored vaccines (Barnes et al., 2012). Very little IL-2 was 406 407 made by CD8⁺ T cells; the overwhelming majority of the IL-2 response came from CD4⁺ T cells on a per individual basis, irrespective of vaccination regimen (Figure 408 409 4C). All groups of participants made polyfunctional T cell responses, which we 410 defined as IFNy/IL-2/TNF triple-positive cells (Figure 4D). There were no differences 411 between vaccine regimens in those with hybrid immunity, who uniformly had 412 polyfunctional responses detectable. 413 414 CD4+ and CD8+ proliferation responses to SARS-CoV2 spike are higher in 415 previously infected participants 416 We also assessed cellular responses to SARS-CoV2 using T cell proliferation, a 417 measure more biased towards central memory responses than IFNy assays. T cell 418 proliferation to spike S1 and S2 peptide pools was higher in previously infected 419 AZD1222 vaccinated and the short interval BNT162b2 group compared to naïve 420 individuals with a 3-8 fold increase in the median responses of CD4⁺ and CD8⁺ T 421 cells respectively (Figure 5A, B and D), thus confirming the enduring increase in 422 cellular memory conferred by infection combined with vaccination. As expected, 423 responses to M and N were absent in the majority of naïve individuals (Figure 5C, E) 424 with only one sample per vaccination regimen showing slightly elevated CD4⁺ T cell 425 proliferation (3-11%) which was not explained by N seroconversion (Figure 5C). 426 Differences between vaccination regimens were only apparent in the BNT162b2 427 vaccinated hybrid immunity groups with significantly increased CD8 responses to S1, 428 S2 and M in the short compared to the long interval. 429

It is made available under a CC-BY-NC-ND 4.0 International license .

The antibody response to SARS-CoV-2 broadens after the third vaccine dose including enhanced neutralisation activity against omicron BA.1

432 Despite the differences between the naïve vaccine groups in binding antibody 6 433 months after the second dose (Figure 2B), there was no significant difference in 434 neutralisation capacity of sera from these participants against the ancestral Victoria 435 strain (Figure 6A). Neutralisation titres were lower against delta and lower still 436 against omicron BA.1 compared with Victoria, as previously described (Dejnirattisai 437 et al., 2022; Schmidt et al., 2021). The BNT162b2 long interval group had higher 438 neutralising titres against delta than the short interval group, as they did 28 days 439 after the second dose (Payne et al., 2021a). Using a surrogate neutralisation assay 440 on the MSD platform, which measures inhibition of spike-ACE2 binding, we 441 measured neutralisation of a wider range of variants. We also observed differences 442 with the BNT162b2 long interval group having higher antibody titres than the other 443 groups (Figure 6B). Although there was a trend for higher titres in the BNT162b2 444 short group compared to the AZD1222 group, this did not reach significance. The 445 surrogate neutralisation assay showed a good correlation with the live virus focus 446 reduction neutralisation assay for Victoria, delta and omicron variants 447 (Supplementary Figure S5).

448

449 After the third dose of vaccine, neutralisation capacity against both the delta and 450 omicron BA.1 variants increased. Our previous report in this cohort demonstrated 451 that the neutralisation of omicron BA.1 was significantly higher 28 days after three 452 doses of BNT162b2 compared to 28 days after 2 doses (Deinirattisai et al., 2022). 453 No differences were observed between vaccine groups after the third dose (Figure 454 6C). These differences also evened out in the ACE2 inhibition assay, though there 455 was some saturation of the assay (Figure 6D). Therefore, although the overall level 456 of binding antibody increased minimally (only in the naïve group) between 28 days 457 after the second and 28 days after the third dose (Figure 3B), the neutralisation 458 capacity of the antibody response broadened, and the gap between groups closed 459 (Figure 6E). Thus, we observed a higher quality of response after the third dose, 460 paralleling what has been seen for clinical effectiveness of a booster dose against 461 omicron.

462

463 In a smaller subset of naïve participants, we extended these analyses to BA.2 and 464 BA.3 (for MSD binding and ACE2 inhibition), 6 months post dose 2 and one month 465 post dose 3. In order to determine the lasting effects of the booster dose on omicron 466 variants post dose 3, we studied a further 115 participants for IgG binding to omicron 467 variants, and 45 participants for live virus neutralisation to omicron BA.1, BA.2 and 468 BA.5 6 months post dose 3. These assays showed that IgG binding to omicron BA.1, 469 2 and 3 spike was lower than that for the ancestral strain but persisted well 6 months 470 after the third dose (Figure 7A-C), including binding to BA.4/5 which we measured at 471 this time point. ACE2 inhibition by antibody was reduced for omicron BA.1-3, and 472 ancestral and omicron responses waned (Figure 7D-F). However, the spread of 473 responses at 6 months post dose 3 was wide, and by this point 11 of the 21

It is made available under a CC-BY-NC-ND 4.0 International license .

474 participants had contracted omicron infections (Figure 7F). Virus neutralisation for 475 BA.1, BA.2 and BA.5 showed similar levels of neutralisation for BA.1 and BA.2, and 476 a slight drop for BA.5 (Figure 7G). These responses waned significantly by 6 477 months, but in the subgroup of 11 people who became infected with between 1 and 478 6 months post dose 3 responses were significantly higher to omicron variants, but 479 not to the ancestral virus (Figure 7G). Neutralisation responses correlated with ACE2 480 inhibition for most participants (Supplementary Figure S5D-I), with some evidence of 481 saturation of the ACE2 assay. Importantly, overall, we detected less waning 6 482 months after the third dose than at the same time point after the second dose. 483 484 Cross reactive T and B cell responses to the omicron variant are preserved 485 compared with the ancestral strain (Victoria) after second and third vaccine doses 486 We investigated the effect of the third vaccine dose on T cell and B cell responses to 487 omicron variants, in recognition of reduced vaccine effectiveness against infection with omicron but preservation of protection against severe disease. First, we tested 488 489 responses to omicron BA.1 at 6 months post dose 2, similar to the situation for many

- 490 people when omicron first appeared in the UK in November 2021. Unlike neutralising 491 antibody responses, which were much lower for omicron BA.1 6 months after the 492 second dose (Figure 6A), and lower but with the gap narrowed after the third dose 493 (Figure 6C), T cell and B cell ELISpot responses were much less impacted. Using 494 flow cytometry in the same participants in whom we studied multiple cytokine 495 responses to spike, we did not detect any differences in the functionality of CD4 or 496 CD8 T cell responses to omicron BA.1 at 6 months post dose 2 (Figure 8A and B). 497 although the total proportion of the IFNy response in CD4⁺ cells dropped slightly 498 (Figure S6A).
- 499

500 Using the more sensitive IFNy ELISpot assay, the proportion of ancestral SARS-501 CoV-2 T cell responses that were relatively preserved for omicron BA.1 on a per 502 individual basis was very high 6 months after the second dose (median 94%, IQR 503 75-110), and one month after a third dose, (median 90%, IQR 70-104), although the 504 difference between ancestral strain and omicron was significant by Wilcoxon 505 matched pairs signed rank test (Figure 8C and D). Analysis of T cell ELISpot 506 responses comparing only the peptides impacted by mutations did reveal a drop 507 (Figure 8E, median 53%, IQR 22 - 75), but this was not enough to have an impact on 508 the T cell response for all of spike. We extended this analysis at 6 months post dose 509 3 for 46 hybrid immune and 28 naïve participants. We tested ancestral SARS-CoV-2 510 spike peptides alongside those from omicron BA.1, BA.2 and BA.4/5 (Figure 8F). At 511 this point, there was no difference detected between the T cell response to any 512 omicron variant in either group by 6 months post third vaccine dose. 513

514 For B cells, responses to omicron BA.1 were lower compared with the ancestral 515 Victoria strain one month after the second dose (median 59% omicron relative to 516 ancestral SARS-CoV-2, IQR 56-67, p=0.0005)(Figure 8G), 6 months after the 517 second dose (median 57% IQR 45-64, p<0.0001)(Figure 8H) and one month after a

third dose, (median 69% IQR 58-78, p<0.0001) (Figure 8I). This still represents a

relative preservation of B cell immunity, compared with the absolute loss of

520 neutralising antibodies to omicron after two vaccines (Figure 6A and C).

521

522 We also measured the effect of omicron on proliferative responses of T cells in some 523 participants. No changes were observed for CD4⁺ and CD8⁺ T cell proliferation in the 524 naïve group, though numbers of naïve participants were limited (Supplementary 525 Figure S6B and D). In the hybrid immunity group, we observed a significant but 526 modest drop in the proliferative response of CD4+ and CD8+ T cells to omicron BA.1 527 spike S2 (Figure S6C, p=0.0115) and S1 pool (Figure S6E, p=0.034) respectively 528 when compared to ancestral spike. Overall, T and B cell responses to the omicron 529 BA.1 variant were well preserved, compared with antibody responses.

530

531 DISCUSSION

532

533 Our study reports robust immunity to SARS-CoV-2 spike including to omicron 534 subvariants for all three primary vaccine regimens - BNT162b2 with a short (3-4 535 week) dosing interval, BNT162b2 with a long (6-17 week) dosing interval, and 536 AZD1222 – following boosting with an mRNA vaccine. Over the course of the 537 COVID-19 pandemic, vaccines have significantly reduced the link between the 538 number of infections with SARS-CoV-2, and the numbers of hospital admissions and 539 deaths due to COVID-19. Although there has been continual evolution of viral 540 variants, which have evaded the antibody response to varying degrees (Harvey et 541 al., 2021), vaccines have retained more effectiveness against severe disease than 542 against overall infection (Andrews et al., 2022; Tartof et al., 2022; UK Health Security 543 Agency, 2022). Emerging evidence implicates T cells as one potential mechanism 544 for this protection, perhaps in addition to non-neutralising antibody functions (Bartsch 545 Yannic et al.; Kaplonek et al., 2022b; Molodtsov et al., 2022; Scurr et al., 2022). The 546 presence of both T cell and antibody responses gives the greatest protection from 547 infection (Molodtsov et al., 2022) and from death in severe disease (Rydyznski 548 Moderbacher et al., 2020), an observation that is also supported by studies in a 549 macaque model (McMahan et al., 2021).

550

551 Here, in a cohort of participants which overlaps with the SIREN study - in which 552 vaccine effectiveness has been shown (Hall et al., 2022), we have observed that 553 responses after a third dose of COVID vaccine have different dynamics: binding and 554 neutralising antibodies wane over the 6 months following the second dose, whereas 555 B and T cell ELISpot responses wane much less over that interval. At 6 months post 556 second dose, T cells secrete multiple cytokines and proliferate, indicating a broad 557 range of memory function is retained by these cells. In addition, T cell responses are 558 higher 6 months after vaccination in uninfected participants than they were in 559 unvaccinated HCW 6 months after wave 1 infection in 2020, in a previous study of 560 this cohort, (Tomic et al., 2022). Our findings are similar to those of Maringer et al. 561 who also found that T cell responses were preserved more than antibody responses

It is made available under a CC-BY-NC-ND 4.0 International license .

562 between the primary course and booster vaccination (Maringer et al., 2022), 563 although we also found a benefit with the third dose, likely due to increased power

- 564 from a much larger sample size.
- 565

566 The third vaccine dose boosted all responses from their nadir post dose 2. The 567 relative magnitude of the T cell boost was smaller compared to the antibody boost 568 but T cell responses had not waned to the same degree prior to the third dose. The 569 third vaccine dose led to peak T cell levels which were higher than their previous 570 peak one-month post second dose. In contrast, the boost to binding antibody 571 response achieved by the third dose did not exceed the previous peak achieved post 572 dose 2. Interestingly, although a third dose of vaccine did not achieve higher peak 573 binding antibody levels, the neutralising capacity of the antibody response was much 574 greater post dose 3 compared to post dose 2 – replicating earlier observations 575 (Dejnirattisai et al., 2022). We observed that the B cell response also declined less in the 6 months after second vaccination than did the neutralising antibody response, 576 577 and this implies many of these cells make antibody which binds, but does not 578 neutralise, the virus.

579

580 With each successive vaccine dose, and up to one month after the third vaccine 581 dose, participants who had been naturally infected with SARS-CoV-2 had their 582 antibody and T cell responses boosted and the absolute values achieved were 583 consistently higher than those who had not been naturally infected. These 584 observations are particularly important when evaluating the relative benefit of a third 585 vaccine dose which we demonstrate achieved statistically significant boosting effects 586 even in the presence of hybrid immunity. These differences finally evened out by 6 587 months after the third dose. The ex-vivo immunogenicity benefits of hybrid immunity 588 demonstrated here align with evidence of the enhanced clinical effectiveness of 589 vaccination in the presence of hybrid immunity (Hall et al., 2022). Superior vaccine 590 effectiveness has also been observed against omicron BA.1, BA.2 and BA.4/5 591 infections in those with hybrid immunity, compared with vaccination or infection alone 592 (Altarawneh et al., 2022; Wei et al., 2022a). A recent systematic review comparing a 593 range of estimates of protection from previous infection, vaccination and hybrid 594 immunity has also found that hybrid immunity provides the greatest and most 595 sustained protection (Bobrovitz et al., 2022).

596

597 We could also still detect an influence of the dose interval of BNT162b2 vaccine at 6 598 months after second vaccination. However, after the third vaccine dose, these 599 differences had largely evened out and were no longer significant between the 600 groups. T cell and antibody responses to spike were lower 6 months after primary 601 vaccination course for AZD1222 compared to either BNT162b2 dosing regimen. 602 These findings are compatible with previous reports for antibodies (Wall et al., 2021; 603 Ward et al., 2022) and lower vaccine effectiveness against infection (UK Health 604 Security Agency, 2022), although vaccine effectiveness against hospitalisation has 605 been well preserved. After the AZD1222-primed recipients received a heterologous

It is made available under a CC-BY-NC-ND 4.0 International license .

606 boost with mRNA vaccine, robust and similar cellular and antibody immunity 607 including against omicron BA.1 variant was seen for all three regimens studied. We 608 detected a possible influence of male sex on reducing T cell responses to a third 609 dose of mRNA vaccine in people who had received a primary course of AZD1222 610 vaccine. However, this finding was based on a small number of participants so must 611 be viewed with caution. The larger parent SIREN study would have greater potential 612 to answer this question definitively, though the public health relevance of this 613 observation is diminishing over time. 614 615 The third dose gave a broad immune response which could recognise all the variants 616 tested. This included neutralisation of the omicron BA.1, BA.2 and BA.5 lineages. 617 The few participants who were followed out to 6 months post dose 3 and had an 618 omicron infection (11 participants) increased their neutralising antibody responses to 619 omicron and not to Victoria, providing no evidence of immune imprinting (or antigenic 620 sin) as has been recently suggested to occur with omicron (Reynolds et al., 2022). 621 More recent population level evidence from Denmark and the UK suggests that 622 omicron BA.1 or BA.2 infection in combination with vaccination is more protective 623 against omicron BA.5 than alpha or delta infection (Hansen et al., 2022; Wei et al., 624 2022a). This may be due to waning immunity, antigenic difference, or both, rather than imprinting. We have not tested the effect of hybrid immunity on subsequent 625

626 responses to omicron; such work is ongoing. However, we found no evidence of 627 antigenic sin for responses after omicron infections, which were larger than the 628 corresponding increase in antibody to the ancestral vaccine virus. T cell responses 629 were less impacted by viral variants that antibodies, likely due to the wider range of 630 epitopes available to T cells compared with antibodies, where protective responses 631 are more focussed. Our findings are in line with those of others, who have also 632 observed that antibodies decline more rapidly than T cell responses (Zhang et al., 633 2022). We found that T cell responses after the third dose were durable out to 6 634 months post dose, and that at this point, overall, ancestral and omicron strains were 635 recognised equally well.

636

637 Our study has a number of limitations. (i) As with other HCW studies, our cohort has 638 a female majority and is predominantly in people reporting white ethnicity. We have 639 not observed any impact of sex or ethnicity in this study or our previous reports 640 (Angyal et al., 2021; Payne et al., 2021a). (ii) Our longitudinal cohort does not 641 include never-vaccinated participants, because all the HCWs engaged with our 642 studies across six sites took up vaccination. However, we have been able to 643 compare responses 6 months after vaccination (in 2021) with historical data using 644 the same assay in a subset of the same cohort in 2020, 6 months after wave 1 645 (ancestral strain) infection before vaccine were available (Tomic et al., 2022) and 646 demonstrate that vaccine-induced responses in infection-naïve HCWs are higher 647 than infection-induced responses. (iii) We were not able to perform all assays on all 648 participants at all timepoints, due to lack of sample availability, missed follow up 649 visits, and/or laboratory capacity. This means that not all our data are longitudinal,

It is made available under a CC-BY-NC-ND 4.0 International license .

650 though many are. To account for this, we have used unpaired testing in all our 651 comparisons. (iv) We only performed neutralising antibody measurements on naïve 652 participants due to the labour intensity and interpretation requiring matching with 653 infecting variant strain and this information was limited. (v) We defined hybrid 654 immunity in participants as previously testing PCR positive for SARS-CoV-2, or 655 seroconversion to anti-N positivity during the study. However, some of the group 656 labelled as naïve could have been exposed to SARS-CoV-2, because up to 60% of 657 vaccinated people may not develop anti-N antibody, and the N sequence differs 658 between variants (Follmann et al., 2022; Whitaker et al., 2021). As time went on, the 659 N antibody levels rose in our naïve participants, even though many remained below 660 the assay threshold for a positive N response. As hybrid immunity evolves in the 661 population it will become increasingly difficult to define the shrinking group of people 662 who have never been infected with SARS-CoV-2. (vi) For people with vaccine 663 breakthrough infections since the second vaccine dose, infecting sequence data was not always available. However, we know that the majority of this report covers a 664 period in time when delta was the predominant variant, with 68% and 88% of the 665 sampling complete for this study by 1st December 2021 and 1st January 2022 666 respectively. (vii) Finally, we have not addressed mucosal immunity in this report, 667 668 this is the subject of ongoing work. Antibody can be readily detected in the mucosa 669 post infection with SARS-CoV-2 (Fröberg et al., 2021). Cellular and antibody 670 responses have been also detected in the mucosa after COVID vaccination (Sano et 671 al., 2022; Ssemaganda et al., 2022), but at low levels and their role in protection 672 remains unclear.

673

674 In summary, we have observed that SARS-CoV-2 specific cellular immune 675 responses are better maintained compared to antibodies in the 6 months following 676 the second dose of COVID-19 vaccine. The third dose of vaccine confers a 677 measurable benefit to these responses irrespective of the primary course, including in people who have previously been infected ("hybrid immunity"), who therefore may 678 679 also stand to benefit from a third dose. The third dose also induces better antibody 680 recognition of SARS-CoV-2 variants, including omicron BA.1. Despite public concern 681 about loss of immunity over time post infection and/or vaccines, we find ample 682 evidence of strong and durable immunity and memory responses that are likely to 683 sustain protection against severe COVID-19 long term. Further booster vaccinations 684 are likely to be most beneficial for preventing severe disease in the clinically 685 vulnerable, and may lead to a reduction in hospitalisation rates. People with immune 686 compromise are now receiving fourth or even fifth vaccine doses in UK and other 687 countries, and parallel studies of durability of immunity in such populations are 688 needed. The role of further booster vaccines for HCWs requires onward longitudinal 689 follow-up of this cohort and others, but prevention of infection in HCWs continues to 690 be desirable to minimise infection-related absence, nosocomial transmission and 691 risks of long COVID (Antonelli et al., 2022). Our findings allow establishment of the 692 dynamics of the immune response post infection and vaccination in a healthy 693 population of working age, which can then be used as a benchmark for evaluating

It is made available under a CC-BY-NC-ND 4.0 International license .

694 immunity in vulnerable groups, and provides the first glimpse of evolving "hybrid 695 immunity" driven by ongoing viral exposure in vaccinated populations.

696

697 METHODS

- 698
- 699 Study design and sample collection

In this prospective, observational, cohort study, participants were recruited into the
 PITCH study from across six centres (Birmingham, Cambridge, Liverpool,

702 Newcastle, Oxford and Sheffield). Individuals consenting to participate were

- recruited by word of mouth, hospital e-mail communications and from hospital-based
- staff screening programmes for SARS-CoV-2, including HCWs enrolled in the
- national SIREN study at three sites (Liverpool, Newcastle and Sheffield). Eligible
- participants were adults aged 18 or over, and currently working as an HCW,
- including allied support and laboratory staff, or were volunteers linked to the hospital.
- The majority of participants were sampled for previous reports in this PITCH cohort

709 (Angyal et al., 2021; Ogbe et al., 2021; Payne et al., 2021a; Skelly et al., 2021).

Participants were sampled for the current study between 4 January 2021 and 15

February 2022, with the majority of the sampling complete before the omicron BA.1

variant emerged in the UK (68% of sampling was prior to December 2021 and 88%
was prior to January 2022).

714

715 Participants had received one of three vaccine regimens: "Short" - two doses of 716 BNT162b2 (Pfizer/BioNTech) administered with the manufacturer's licenced dosing 717 interval (median 24 days, IQR 21-27); "Long" - two doses of BNT162b2 718 (Pfizer/BioNTech) administered with an extended dosing interval (median 71 days, 719 IQR 66-78); and "AZ" - two doses of AZD1222 (Oxford/AstraZeneca), administered a 720 median 74 days (IQR 65-78) apart. All participants then received a third "booster" 721 dose of BNT162b2, a median of 207 days, (IQR 191-233) days after the second 722 dose, regardless of primary vaccine regimen. Participants underwent phlebotomy for 723 assessment of immune responses one (median 28 days, IQR 26-32) and six 724 (median 185 days, IQR 173-200) months after the second dose of vaccine, and one 725 month after the third dose of vaccine (median 31 days, IQR 28-37). Clinical 726 information including BNT162b2 and AZD1222 vaccination dates, date of any SARS-727 CoV-2 infection (either prior to vaccination or during the study) defined by a positive 728 PCR test and/or detection of antibodies to spike or nucleocapsid protein, presence or 729 absence of symptoms, time between symptom onset and sampling, age, sex and 730 ethnicity of participant was recorded. Key information on demographics and vaccine 731 dose intervals is shown in Table 1. 732

Participants were considered to be SARS-CoV-2 exposed if they had ever been PCR
 or lateral flow device positive for SARS-CoV-2, irrespective of symptoms. In addition,
 participants were considered exposed to SARS-CoV-2 if they seroconverted with N
 antibody on the mesoscale discovery (MSD) assay. N seroconversion was defined
 as an N antibody level over the cut-off threshold of 3874 previously defined using

pre-pandemic samples (Payne et al., 2021b), and at least a 2-fold increase over the
baseline value. Participants who did not meet any of these criteria were considered
to be infection-naïve.

741

742 PITCH is a sub-study of the SIREN study, which was approved by the Berkshire Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC 743 reference 20/SC/0230), with PITCH recognised as a sub-study on 2 December 2020. 744 745 SIREN is registered with ISRCTN (Trial ID:252 ISRCTN11041050). Some 746 participants were recruited under aligned study protocols. In Birmingham participants 747 were recruited under the Determining the immune response to SARS-CoV-2 748 infection in convalescent health care workers (COCO) study (IRAS ID: 282525). In Liverpool some participants were recruited under the "Human immune responses to 749 750 acute virus infections" Study (16/NW/0170), approved by North West - Liverpool 751 Central Research Ethics Committee on 8 March 2016, and amended on 14th September 2020 and 4th May 2021. In Oxford, participants were recruited under the 752 753 GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016, 754 755 which has been amended for this purpose on 8 June 2020. In Sheffield, participants 756 were recruited under the Observational Biobanking study STHObs (18/YH/0441), 757 which was amended for this study on 10 September 2020. We also included some 758 participants from Cambridge from a study approved by the National Research Ethics Committee and Health Research Authority (East of England – Cambridge Research 759 760 Ethics Committee (SCORPIO study, SARS-CoV-2 vaccination response in obesity amendment of "NIHR BioResource" 17/EE/0025). The study was conducted in 761 762 compliance with all relevant ethical regulations for work with human participants, and 763 according to the principles of the Declaration of Helsinki (2008) and the International 764 Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. 765 Written informed consent was obtained for all participants enrolled in the study. 766 767 Peripheral blood mononuclear cells (PBMCs), plasma and serum were separated 768 and cryopreserved. Some of the immune response data from one month after the 769 second dose has been previously reported (Payne et al., 2021a), as has some of the 770 neutralising antibody data for HCWs receiving a short dosing interval for BNT162b2

771 (Dejnirattisai et al., 2022). The study size was selected because this number was

- feasible for the six clinical and laboratory sites to study, and consistent with our trackrecord of significant findings at this scale.
- 774
- 775 Meso Scale Discovery (MSD) IgG binding assay
- IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and seasonal
- coronaviruses were measured using a multiplexed MSD immunoassay: The V-PLEX
- 778 COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale
- 779 Discovery, Rockville, MD USA. A MULTI-SPOT® 96-well, 10 spot plate was coated
- vith three SARS CoV-2 antigens (Spike (S), Receptor-Binding Domain (RBD),
- 781 Nucleoprotein (N)), SARS-CoV-1 and MERS-CoV spike trimers, spike proteins from

It is made available under a CC-BY-NC-ND 4.0 International license .

782 seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-229E and HCoV-783 NL63, and bovine serum albumin (negative control). Antigens were spotted at 200–400 µg/mL (MSD[®] Coronavirus Plate 3). Multiplex MSD assays were performed 784 785 as per the manufacturer's instructions. To measure IgG antibodies, 96-well plates 786 were blocked with MSD Blocker A for 30 minutes. Following washing with washing 787 buffer, samples diluted 1:1,000-30,000 in diluent buffer, MSD standard and undiluted internal MSD controls, were added to the wells. After 2-hour incubation and a 788 789 washing step, detection antibody (MSD SULFO-TAG[™] anti-human IgG antibody, 790 1/200) was added. Following washing, MSD GOLD[™] read buffer B was added and plates were read using a MESO[®] SECTOR S 600 reader. The standard curve was 791 established by fitting the signals from the standard using a 4-parameter logistic 792 793 model. Concentrations of samples were determined from the 794 electrochemiluminescence signals by back-fitting to the standard curve and 795 multiplying by the dilution factor. Concentrations are expressed in Arbitrary Units/ml 796 (AU/ml). Cut-offs were determined for each SARS-CoV-2 antigen (S, RBD and N) 797 based on the mean concentrations measured in 103 pre-pandemic sera + 3 Standard Deviations. Cut-offs were: S, 1160 AU/ml; RBD, 1169 AU/ml; and N, 3874 798 799 AU/ml. 800 801 MSD ACE2 inhibition assay The V-PLEX SARS-CoV-2 Panel 23 (ACE2) Kit, from MSD, Rockville, MD, a 802 803 multiplexed MSD immunoassay, was also used to measure the ability of human sera 804 to inhibit ACE2 binding to SARS-CoV-2 spike antigens including B (Victoria). 805 B.1.1.7/alpha, B.1.351/beta P.1/gamma, B.1.617.2/delta or B.1.1.529; BA.1/omicron 806 BA.1). A MULTI-SPOT 96-well, 10 spot plate was coated with SARS-CoV-2 spike 807 antigens including these ones above-mentioned. Multiplex MSD Assays were 808 performed as per manufacturer's instructions. To measure ACE2 inhibition, 96-well 809 plates were blocked with MSD Blocker for 30 minutes. Plates were then washed in 810 MSD washing buffer, and samples were diluted 1:10 – 1:100 in diluent buffer. 811 Neutralizing activity was determined by measuring the presence of antibodies able to 812 block the binding of ACE2 to SARS-CoV-2 spike proteins from Victoria spike, 813 B.1.1.7/alpha, B.1.617.2/delta, B.1.351/beta, P.1/gamma and B.1.1.529; 814 BA.1/omicron BA.1 and was expressed as percentage of ACE2 inhibition in 815 comparison to the blanks on the same plate. Furthermore, internal controls and the 816 WHO SARS-CoV-2 Immunoglobulin international standard (NIBSC 20/136) were 817 added to each plate. After a 1-hour incubation, recombinant human ACE2-SULFO-818 TAG was added to all wells. After a further 1-hour, plates were washed and MSD 819 GOLD Read Buffer B was added, plates were then immediately read using a MESO 820 SECTOR S 600 Reader.

821

822 Focus Reduction Neutralisation Assay (FRNT)

- 823 The neutralisation potential of antibodies (Ab) was measured using a Focus
- 824 Reduction Neutralisation Test (FRNT), where the reduction in the number of the
- 825 infected foci is compared to a negative control well without antibody. Briefly, serially

It is made available under a CC-BY-NC-ND 4.0 International license .

826 diluted Ab or plasma was mixed with SARS-CoV-2 strain Victoria or P.1 and 827 incubated for 1 hr at 37C. The mixtures were then transferred to 96-well, cell culture-828 treated, flat-bottom microplates containing confluent Vero cell monolayers in 829 duplicate and incubated for a further 2 hr followed by the addition of 1.5% semi-solid 830 carboxymethyl cellulose (Sigma) overlay medium to each well to limit virus diffusion. 831 A focus forming assay was then performed by staining Vero cells with human anti-832 nucleocapsid monoclonal Ab (mAb206) followed by peroxidase-conjugated goat anti-833 human IgG (A0170; Sigma). Finally, the foci (infected cells) approximately 100 per 834 well in the absence of antibodies, were visualized by adding TrueBlue Peroxidase 835 Substrate (Insight Biotechnology). Virus-infected cell foci were counted on the 836 classic AID ELISpot reader using AID ELISpot software. The percentage of focus 837 reduction was calculated and IC50 was determined using the probit program from 838 the SPSS package. In order to reduce confounding arising from exposure to different 839 SARS-CoV-2 variants, these experiments were conducted only on participants who 840 were naive at the time of sampling 6-months post second vaccine dose, as defined 841 by no history of positive PCR or lateral flow test for SARS-CoV-2, and no anti-N IgG 842 seroconversion during the study.

843

844 T cell interferon-gamma (IFNy) ELISpot Assay

845 The PITCH ELISpot Standard Operating Procedure has been published previously 846 (Angyal et al., 2021). Interferon-gamma (IFNy) ELISpot assays were set up from 847 cryopreserved PBMCs using the Human IFNy ELISpot Basic kit (Mabtech 3420-2A). 848 A single protocol was agreed across the centres as previously published (Angyal et 849 al., 2021) and available on the PITCH website (http://www.pitch-study.org/). 850 In brief, PBMCs were thawed and rested for 3-6 hours in R10 media: RPMI 1640 851 (Sigma) supplemented with 10% (v/v) Fetal Bovine Serum (Sigma), 2mM L-852 Glutamine (Sigma) and 1mM Penicillin/Streptomycin (Sigma) in a humidified 853 incubator at 37°C, 5% CO₂, prior to stimulation with peptides. PBMCs were then 854 plated in duplicate or triplicate at 200,000 cells/well in a MultiScreen-IP filter plate 855 (Millipore, MAIPS4510) previously coated with capture antibody (clone 1-D1K) and 856 blocked with R10. PBMCs were then stimulated with overlapping peptide pools (18-857 mers with 10 amino acid overlap, Mimotopes) representing the spike (S), Membrane 858 (M) or nucleocapsid (N) SARS-CoV-2 proteins at a final concentration of 2 µg/ml for 859 16 to 18 hours in a humidified incubator at 37°C, 5% CO₂. For selected individuals, 860 pools representing spike protein of the Omicron (BA.1) variant were included. Pools 861 consisting of CMV, EBV and influenza peptides at a final concentration of 2µg/ml 862 (CEF; Proimmune) and concanavalin A or phytohemagglutinin L (PHA-L, Sigma) 863 were used as positive controls. DMSO was used as the negative control at an 864 equivalent concentration to the peptides. After the incubation period as well as all 865 subsequent steps wells were washed with PBS/0.05% (v/v) Tween20 (Sigma). Wells 866 were incubated with biotinylated detection antibody (clone 7-B6-1) followed by 867 incubation with the ELISpot Basic kit streptavidin-ALP. Finally colour development 868 was carried out using the 1-step NBT/BCIP substrate solution (Thermo Scientific) for 869 5 minutes at RT. Colour development was stopped by washing the wells with tap

It is made available under a CC-BY-NC-ND 4.0 International license .

870 water. Air dried plates were scanned and analysed with either the AID Classic 871 ELISpot reader (software version 8.0, Autoimmune Diagnostika GmbH, Germany) or 872 the ImmunoSpot® S6 Alfa Analyser (Cellular Technology Limited LLC, Germany). 873 Antigen-specific responses were quantified by subtracting the mean spots of the 874 negative control wells from the test wells and the results were expressed as spotforming units (SFU)/10⁶ PBMCs. Samples with a mean spot value greater than 50 875 spots in the negative control wells were excluded from the analysis. 876 877 878 For comparison of responses to omicron BA.1 we firstly compared responses to 178 879 peptides spanning all of spike (S1 and S2) for the ancestral (wild type) and the 880 omicron BA.1 variant, then secondly, we compared responses to the 51 peptides 881 representing the regions of spike with mutations in omicron BA.1, again comparing 882 ancestral and omicron BA.1. To reduce the disproportionate impact of background noise, samples with a total response to ancestral spike of <33 SFU/10⁶ PBMCs were 883 excluded from analysis, with this cut off threshold calculated as the mean + 2 884 885 standard deviations of the DMSO wells across all experiments in the study. The % of 886 the T cell response to ancestral strain that was preserved against omicron BA.1 was 887 calculated for each paired sample then expressed as the median and IQR for the 888 group.

889

890 Memory B cell Fluorospot assay

Cryopreserved PBMCs were thawed and cultured for 72 hours with polyclonal 891 892 stimulation containing 1 µg/ml R848 and 10 ng/ml IL-2 from the Human memory B 893 cell stimpack (Mabtech). Using the Human IgA/IgG FluoroSpotFLEX kit (Mabtech), 894 stimulated PBMCs were then added at 2x10⁵ cells/well to fluorospot plates coated 895 with 10 µg/ml Sars-CoV-2 spike glycoprotein diluted in PBS. Plates were incubated 896 for 16 hours in a humidified incubator at 37°C, 5% CO₂ and developed according to 897 the manufacturer's instructions (Mabtech). Analysis was carried out with AID ELISpot 898 software 8.0 (Autoimmun Diagnostika). All samples were tested in triplicates and 899 response was measured as spike-specific spots per million PBMCs with PBS 900 background subtracted.

901

902 Intracellular cytokine stimulation assay

903 In a subset of donors (n=95), selected at random from all three vaccine regimens 904 and previous SARS-CoV-2 infection, T cell responses were characterised further 905 using intracellular cytokine staining (ICS) after stimulation with overlapping SARS-CoV2 peptide pools. In brief, cryopreserved PBMCs were thawed, rested for 4-5 906 907 hours in R10 media and then plated at 1x10⁶ cells/well in a 96 well U-bottom plate 908 together with co-stimulatory molecules anti-CD28 and anti-CD49d (both BD). Peptide 909 pools (spanning ancestral (B.1) spike, omicron BA.1 spike, ancestral membrane (M) 910 and nucleocapsid (N) proteins) were added at 2 µg/ml final concentration for each 911 peptide. DMSO (Sigma) was used as the negative control at the equivalent 912 concentration to the peptides. As a positive control, cells were stimulated with 1x cell 913 activation cocktail containing phorbol-12-myristate 13-acetate (PMA) at 81µM and

914 ionomycin at 1.3µM final concentration (Biolegend). The cells were then incubated in
915 a humidified incubator at 37°C, 5% CO₂ for 1 hour before incubating for a further 15
916 hours in the presence of 5µg/ml Brefeldin A (Biolegend). Flow cytometry staining
917 was performed as described below.

918

919 Proliferation assay

920 T cell proliferation assessed the magnitude of memory responses to SARS-CoV2 921 spike, M and N protein in the CD4⁺ and CD8⁺ T cell pool in 73 individuals selected 922 for the ICS assay, with 27 participants from the BNT162b2 short interval group (16 923 naïve and 11 with hybrid immunity), 27 participants from the BNT162b2 long interval 924 group (15 naïve and 12 with hybrid immunity) and 19 participants from the AZD1222 group (8 naïve and 11 with hybrid immunity). CellTrace[™] Violet (CTV, Invitrogen) 925 labelling and stimulation with SARS-CoV-2 peptide pools spanning ancestral spike 926 927 (divided into two pools, S1 and S2), omicron (BA.1) spike (S1 and S2), ancestral M 928 and N protein, as well as a control peptide mix, CEF (1µg/ml per peptide) was 929 carried out as previously described (Ogbe et al., 2021). Cells were incubated in 930 RPMI 1640 (Sigma) supplemented with 10% human AB serum (Sigma), 2mM L-931 glutamine (Sigma) and 1 mM Penicillin/Streptomycin (Sigma) in a 96 well U-bottom 932 plate at 250,000 cells per well in single or duplicate depending on cell availability. 933 DMSO added at the same concentration to SARS-CoV-2 peptides served as 934 negative control and 2ug/ml PHA-L as positive control. Cells were placed in a 935 humidified incubator at 37°C, 5% CO₂. Half a media change was performed on day 4 936 and cells were harvested for flow cytometry staining on day 7 as described below. 937 Data were expressed as relative frequency of proliferating cells within single, live 938 CD4+ T cells and CD8+ T cells respectively. Background was subtracted from 939 stimulated samples and samples were excluded due to high background (DMSO 940 control >2% proliferation in any T cell subset.) or less than 1000 events in the single. 941 live CD3+ gate (10 samples in total were excluded). Responses to individual peptide 942 pools and summed responses to total spike (S1+S2) and M+NP were reported.

943 944

945 Flow cytometry straining and analysis

946 Details for antibodies are listed in Supplementary Table 2. All washes and 947 extracellular staining steps for PBMC were carried out in cell staining buffer 948 (Biolegend) for ICS samples and PBS for proliferation samples. At the end of the 949 culture period, PBMCs were washed once and subsequently stained with near-950 infrared fixable live/dead stain (Invitrogen) together with a cocktail of fluorochrome-951 conjugated primary human-specific antibodies against CD4, CD8, CD14 (all 952 Biolegend) as well as human Fc blocking reagent (Miltenyi Biotec) for ICS and CD3, 953 CD4 and CD8 (all Biolegend) for proliferation samples. Cells were stained at 4°C in 954 the dark for 20 minutes, followed by one wash. Proliferation samples were then fixed 955 with a 4% formaldehyde solution (Sigma) for 10min at 4°C, washed and stored in 956 PBS in the fridge for up to one day. ICS samples were fixed and permeabilized in 957 Cytofix/Cytoperm buffer (BD) for 20 min at 4°C, washed with 1x Perm buffer (BD)

It is made available under a CC-BY-NC-ND 4.0 International license .

once followed by staining with the following primary human-specific antibodies
diluted in Perm buffer: CD3, IFN-γ, TNF (all Biolegend), IL-2 (eBioscience) for 20 min
at 4°C followed by one wash in 1x Perm buffer. Cells were stored in cell staining
buffer in the fridge for up to one day. Samples were acquired on a MACSQuant

962 analyser 10 and X (Miltenyi Biotec) and analysis was performed using FlowJo

- 963 software version 10.8.1 (BD Biosciences). Example gating strategies are shown in
- 964 Supplementary Figure 1.
- 965

966 Statistical analysis

967 Continuous variables are displayed with median and interquartile range (IQR).

968 Unpaired comparisons across two groups were performed using the Mann-Whitney

969 test, and across three groups using the Kruskal-Wallis test with Dunn's multiple

970 comparisons test. Paired comparisons were performed using the Wilcoxon matched

- pairs signed rank test. Two-tailed P values are displayed. Statistical analyses were
- done using R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria.
- 973 URL https://www.R-project.org/) using the tidyverse packages (Wickham et al., 2019)
- and GraphPad Prism 9.3.1.
- 975

It is made available under a CC-BY-NC-ND 4.0 International license .

976 ACKNOWLEDGEMENTS

977 We are grateful to all our healthcare worker colleagues who participated in the study.

978 For the Birmingham participants, the study was carried out at the National Institute

979 for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility.

980 Laboratory studies were undertaken by the Clinical Immunology Service, University

- 981 of Birmingham.
- 982

983

984 AUTHOR CONTRIBUTIONS

985 Conceptualization, L.T., S.J.D., P.K., T.dS., S.H., V.H., C.J.A.D., R.P.P., A.R., M.C., G.S.; 986 Methodology, S.J.D., P.K., L.T., S.C.M., B.K., S.L., T.dS., C.J.A.D., A.R., M.C., G.S., C.D., 987 N.G., S.H., V.H.; Formal Analysis, B.K., S.C.M., S.J.D., L.T., T.dS., C.D., S.L., D.T.S., W.D., 988 A.S.D., S.A., J.D.W. Investigation, B.K., R.P.P., S.L., C.L., W.D., S.A., N.M., S.F., S.A-T., 989 S.C.M., T.T., L.M.H., A.A., R.B., A.R.N., S.L.D., E.C.H., L.H.B., P.S., A.C., A.B-W., L.S.R., 990 A.L., J.K.T., H.H., I.G., M.P., P.Z., T.A.H.N., J.M.N., P.A., E.P., T.M., I.N., A.H., A.Sh., L.S., 991 D.G.W., A.B.; Resources, A.B., L.T., E.B.; Data Curation, S.C.M., A.D.; Writing – Original 992 Draft, L.T., S.J.D., P.K., Writing – Review & Editing, B.K., S.C.M., S.L., T.dS., S.L.D., S.J., 993 D.G.W., C.P.C., K.J., P.C.M., A.J.P., J.M., E.B., A.R., M.C., G.S.; Visualization, S.C.M., S.L., 994 B.K., S.A., J.D.W., L.T., S.J.D., Supervision, B.K., C.P.C., K.J., J.F., A.J.P., S.L.R-J., 995 J.E.D.T., R.P.P., J.M., E.B., S.H., V.H., C.D., C.J.A.D., A.R., M.C., G.S., T.dS., L.T., P.K., 996 S.J.D., Project Administration, A.S.D., Funding Acquisition, P.K., S.J.D., L.T., T.dS., 997 C.J.A.D., A.R., S.H., V.H.

998

999 1000 DECLARATION OF INTERESTS

1001 This work was funded by the UK Department of Health and Social Care as part of 1002 the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) 1003 Consortium, UKRI as part of "Investigation of proven vaccine breakthrough by 1004 SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN 1005 consortium & PITCH Plus Pathway" MR/W02067X/1, with contributions from 1006 UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo 1007 Family Foundation and The National Institute for Health Research (UKRIDHSC 1008 COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19-1009 RECPLAS).

1010

1011 E.B. and P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA.

1012 S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.dS is

1013 funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). RPP

1014 is funded by a Career Re-entry Fellowship (204721/Z/16/Z). C.J.A.D. is funded by a

1015 Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z). J.M.

and G.S. are funded by the Chinese Academy of Medical Sciences (CAMS)

1017 Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-

1018 002), Schmidt Futures, the Red Avenue Foundation and the Oak Foundation. The

1019 Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant

1020 090532/Z/09/Z). P.C.M. is funded by Wellcome (110110z/15/Z), the Francis Crick

It is made available under a CC-BY-NC-ND 4.0 International license .

1021 Institute, and the University College London Hospital NIHR Biomedical Research 1022 Centre, J.E.D.T. is supported by the Medical Research Council (MR/W020564/1) 1023 and (MC_UU_0025/12). L.T. is supported by the Wellcome Trust (grant number 1024 205228/Z/16/Z), the National Institute for Health Research Health Protection 1025 Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (EZI) (NIHR200907) and the Centre of Excellence in Infectious Diseases Research 1026 (CEIDR) and the Alder Hey Charity. The HPRU-EZI at University of Liverpool is in 1027 partnership with UK Health Security Agency (UKHSA), in collaboration with Liverpool 1028 1029 School of Tropical Medicine and the University of Oxford. D.G.W. is supported by an 1030 NIHR Advanced Fellowship in Liverpool. M.C., S.L., L.T., and T.T. are supported by U.S. Food and Drug Administration Medical Countermeasures Initiative contract 1031 1032 75F40120C00085. The Sheffield Teaching Hospitals Observational Study of Patients 1033 with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-1034 ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STH-1035 ObS Chief Investigator Allan Laurie is supported by a British Heart Foundation Senior Basic Science Research fellowship (FS/18/52/33808). We gratefully 1036 acknowledge financial support from the UK Department of Health and Social Care 1037 1038 via the Sheffield NIHR Clinical Research Facility award to the Sheffield Teaching Hospitals Foundation NHS Trust. 1039 1040 1041 The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or Public Health England 1042 1043 or the US Food and Drug Administration. 1044 1045 S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she receives a fee. A.J.P. is Chair of UK Dept. Health and Social Care's (DHSC) Joint 1046 1047 Committee on Vaccination & Immunisation (JCVI), but does not participate in policy 1048 decisions on COVID-19 vaccines. He was previously a member of the WHO's 1049 SAGE. The views expressed in this article do not necessarily represent the views of 1050 DHSC, JCVI, or WHO. AJP is chief investigator on clinical trials of Oxford 1051 University's COVID-19 vaccine funded by NIHR. Oxford University has entered a joint COVID-19 vaccine development partnership with AstraZeneca. G.S. sits on the 1052 1053 GSK Vaccines Scientific Advisory Board and is a founder member of RQ 1054 Biotechnology. 1055 1056 1057 1058 1059 1060

It is made available under a CC-BY-NC-ND 4.0 International license .

1061 **REFERENCES**

1062

Addetia, A., Crawford Katharine, H.D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.L., Jerome Keith, R., Bloom Jesse, D., Greninger Alexander, L., and McAdam Alexander, J.
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a
Fishery Vessel Outbreak with a High Attack Rate. Journal of Clinical Microbiology *58*,
e02107-02120.

Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Yassine, H.M., AlKhatib, H.A., Smatti, M.K., Coyle, P., Al-Kanaani, Z., *et al.* (2022). Effects of Previous
Infection and Vaccination on Symptomatic Omicron Infections. New England Journal of
Medicine 387, 21-34.

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall,
M., Groves, N., O'Connell, A.-M., *et al.* (2022). Covid-19 Vaccine Effectiveness against the
Omicron (B.1.1.529) Variant. New England Journal of Medicine *386*, 1532-1546.

Angyal, A., Longet, S., Moore, S.C., Payne, R.P., Harding, A., Tipton, T., Rongkard, P., Ali,
M., Hering, L.M., Meardon, N., *et al.* (2021). T-cell and antibody responses to first BNT162b2
vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a
multicentre prospective cohort study. Lancet Microbe.

Antonelli, M., Penfold, R.S., Merino, J., Sudre, C.H., Molteni, E., Berry, S., Canas, L.S.,
Graham, M.S., Klaser, K., Modat, M., *et al.* (2022). Risk factors and disease profile of postvaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a
prospective, community-based, nested, case-control study. The Lancet Infectious Diseases
22, 43-55.

Barnes, E., Folgori, A., Capone, S., Swadling, L., Aston, S., Kurioka, A., Meyer, J., Huddart,
R., Smith, K., Townsend, R., *et al.* (2012). Novel adenovirus-based vaccines induce broad
and sustained T cell responses to HCV in man. Sci Transl Med *4*, 115ra111.

Bartsch Yannic, C., Tong, X., Kang, J., Avendaño María, J., Serrano Eileen, F., GarcíaSalum, T., Pardo-Roa, C., Riquelme, A., Cai, Y., Renzi, I., *et al.* Omicron variant Spikespecific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated
COVID-19 vaccines. Science Translational Medicine *14*, eabn9243.

Bobrovitz, N., Ware, H., Ma, X., Li, Z., Hosseini, R., Cao, C., Selemon, A., Whelan, M.,
Premji, Z., Issa, H., *et al.* (2022). Protective effectiveness of prior SARS-CoV-2 infection and
hybrid immunity against Omicron infection and severe disease: a systematic review and
meta-regression. medRxiv, 2022.2010.2002.22280610.

Carazo, S., Skowronski, D.M., Brisson, M., Sauvageau, C., Brousseau, N., Gilca, R., Ouakki,
M., Barkati, S., Fafard, J., Talbot, D., *et al.* (2022). Protection against Omicron re-infection
conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination.
medRxiv, 2022.2004.2029.22274455.

De Marco, L., D'Orso, S., Pirronello, M., Verdiani, A., Termine, A., Fabrizio, C., Capone, A.,
Sabatini, A., Guerrera, G., Placido, R., *et al.* (2022). Assessment of T-cell Reactivity to the
SARS-CoV-2 Omicron Variant by Immunized Individuals. JAMA Network Open *5*, e2210871e2210871.

Dejnirattisai, W., Huo, J., Zhou, D., Zahradnik, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E.,
Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., *et al.* (2022). SARS-CoV-2 Omicron-B.1.1.529
leads to widespread escape from neutralizing antibody responses. Cell *185*, 467-484 e415.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 1106 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,
- 1107 Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for COVID-
- 1108 19 vaccines. Vaccine 39, 4423-4428.

Ewer, K.J., Barrett, J.R., Belij-Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R.,
Flaxman, A., Wright, D., Bellamy, D., Bittaye, M., *et al.* (2021). T cell and antibody responses
induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical
trial. Nat Med *27*, 270-278.

Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M.,
Gilbert, S.C., Hirsch, I., *et al.* (2021). Correlates of protection against symptomatic and
asymptomatic SARS-CoV-2 infection. Nature Medicine *27*, 2032-2040.

Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,
Desjardins, M., Corey, L., Neuzil, K.M., *et al.* (2022). Antinucleocapsid Antibodies After
SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med, DOI: 10.7326/M7322-1300.

Fröberg, J., Gillard, J., Philipsen, R., Lanke, K., Rust, J., Van Tuijl, D., Teelen, K., Bousema,
T., Simonetti, E., Van Der Gaast-De Jongh, C.E., *et al.* (2021). SARS-CoV-2 mucosal
antibody development and persistence and their relation to viral load and COVID-19
symptoms. Nature Communications *12*.

Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,
Österborg, A., Bergman, P., *et al.* (2022). Ancestral SARS-CoV-2-specific T cells crossrecognize the Omicron variant. Nature Medicine *28*, 472-476.

1126 recognize the Omicron variant. Nature Medicine 28, 472-476.

GeurtsvanKessel Corine, H., Geers, D., Schmitz Katharina, S., Mykytyn Anna, Z., Lamers
Mart, M., Bogers, S., Scherbeijn, S., Gommers, L., Sablerolles Roos, S.G., Nieuwkoop Nella,
N., *et al.* (2022). Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in

1130 COVID-19 vaccine recipients. Science Immunology 7, eabo2202.

Gilbert, P.B., Montefiori David, C., McDermott Adrian, B., Fong, Y., Benkeser, D., Deng, W.,
Zhou, H., Houchens Christopher, R., Martins, K., Jayashankar, L., *et al.* (2022). Immune
correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science *375*,
43-50.

Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L., Haas, E.J., Milo,
R., Alroy-Preis, S., Ash, N., and Huppert, A. (2021). Waning Immunity after the BNT162b2
Vaccine in Israel. N Engl J Med *385*, e85.

- Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,
- 1139 Munro, K., Cole, M., et al. (2022). Protection against SARS-CoV-2 after Covid-19
- 1140 Vaccination and Previous Infection. New England Journal of Medicine 386, 1207-1220.

Hall, V.J., Foulkes, S., Charlett, A., Atti, A., Monk, E.J.M., Simmons, R., Wellington, E., Cole,

- 1142 M.J., Saei, A., Oguti, B., *et al.* (2021a). SARS-CoV-2 infection rates of antibody-positive 1143 compared with antibody-negative health-care workers in England: a large, multicentre,
- 1144 prospective cohort study (SIREN). Lancet 397, 1459-1469.
- Hall, V.J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe,
- 1146 J., Gillson, N., Atti, A., et al. (2021b). COVID-19 vaccine coverage in health-care workers in
- 1147 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
- 1148 prospective, multicentre, cohort study. Lancet 397, 1725-1735.

Hansen, C.H., Friis, U.F., Bager, P., Stegger, M., Fonager, J., Fomsgaard, A., Gram, M.A.,
Christiansen, L.E., Ethelberg, S., Legarth, R., *et al.* (2022). Risk of reinfection, vaccine
protection, and severity of infection with the BA.5 omicron subvariant: a Danish nation-wide
population-based study. Available at SSRN: .

Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M.,
Ludden, C., Reeve, R., Rambaut, A., Peacock, S.J., *et al.* (2021). SARS-CoV-2 variants,
spike mutations and immune escape. Nature Reviews Microbiology *19*, 409-424.

Kaplonek, P., Cizmeci, D., Fischinger, S., Collier, A.-r., Suscovich, T., Linde, C., Broge, T.,
Mann, C., Amanat, F., Dayal, D., *et al.* (2022a). mRNA-1273 and BNT162b2 COVID-19
vaccines elicit antibodies with differences in Fc-mediated effector functions. Science

1159 Translational Medicine 14, eabm2311.

Kaplonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y.C., Kang, J., Burke, J.S., Shin, S.A.,
Dayal, D., Martin, P., Mann, C., *et al.* (2022b). mRNA-1273 vaccine-induced antibodies
maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity *55*, 355365.e354.

1164 Kedzierska, K., and Thomas, P.G. (2022). Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Reports Medicine *3*, 100562.

Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele,
S., Bernstein, M., Karim, F., *et al.* (2022). T cell responses to SARS-CoV-2 spike crossrecognize Omicron. Nature *603*, 488-492.

Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are
highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature
Medicine *27*, 1205-1211.

Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez, N.D., Conibear, E.,
Koycheva, A., Davies, M., Tolosa-Wright, M., *et al.* (2022). Cross-reactive memory T cells
associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nature
Communications *13*, 80.

Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S., Sunny, S.-K., Moore, Z., and Zeng,
D. (2022). Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. New
England Journal of Medicine *386*, 933-941.

Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K.,
Sciacca, M., VanWyk, H., Wu, C., *et al.* (2022). Vaccines elicit highly conserved cellular
immunity to SARS-CoV-2 Omicron. Nature *603*, 493-496.

Madelon, N., Heikkilä, N., Sabater Royo, I., Fontannaz, P., Breville, G., Lauper, K.,
Goldstein, R., Grifoni, A., Sette, A., Siegrist, C.-A., *et al.* (2022). Omicron-Specific Cytotoxic
T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With

1186 Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurology.

Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Horber, S., Peter, A., Karbach,
J., Jager, E., and Walz, J.S. (2022). Durable spike-specific T-cell responses after different
COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci
Immunol, eadd3899.

McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
Peter, L., Atyeo, C., Zhu, A., *et al.* (2021). Correlates of protection against SARS-CoV-2 in
rhesus macaques. Nature *590*, 630-634.

Mefsin, Y., Chen, D., Bond, H.S., Lin, Y., Cheung, J.K., Wong, J.Y., Ali, S.T., Lau, E.H.Y.,
Wu, P., Leung, G.M., *et al.* (2022). Epidemiology of infections with SARS-CoV-2 Omicron
BA.2 variant in Hong Kong, January-March 2022. medRxiv, 2022.2004.2007.22273595.

Molodtsov, I.A., Kegeles, E., Mitin, A.N., Mityaeva, O., Musatova, O.E., Panova, A.E.,
Pashenkov, M.V., Peshkova, I.O., Alsalloum, A., Asaad, W., *et al.* (2022). Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in
Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. Clinical Infectious
Diseases 75, e1-e9.

Moore, P.L., Moyo-Gwete, T., Hermanus, T., Kgagudi, P., Ayres, F., Makhado, Z., Sadoff, J.,
Le Gars, M., van Roey, G., Crowther, C., *et al.* (2021). Neutralizing antibodies elicited by the
Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite
protection against severe disease by this variant. bioRxiv, DOI: 2021.2006.2009.447722.

Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L.,
Rumm, A.P., Maruste, R., Kärner, J., *et al.* (2021). Dynamics of antibody response to
BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional
Health – Europe *10*.

Nyberg, T., Ferguson, N.M., Nash, S.G., Webster, H.H., Flaxman, S., Andrews, N., Hinsley,
W., Bernal, J.L., Kall, M., Bhatt, S., *et al.* (2022). Comparative analysis of the risks of
hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta
(B.1.617.2) variants in England: a cohort study. The Lancet *399*, 1303-1312.

Ogbe, A., Kronsteiner, B., Skelly, D.T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter,
H.D., Ali, M., Ali, S.-E., *et al.* (2021). T cell assays differentiate clinical and subclinical SARSCoV-2 infections from cross-reactive antiviral responses. Nat Commun *12*, 2055.

Otter, A.D., D'Arcangelo, S., Whitaker, H., Hewson, J., Foulkes, S., Atti, A., Cole, M., Linley,
E., Tonge, S., Hettiarachchi, N., *et al.* (2022). Determinants of SARS-CoV-2 anti-spike
antibody levels following BNT162b2 vaccination: cross-sectional analysis of 6,000 SIREN
study participants. medRxiv, 2022.2004.2021.22274025.

Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B.,
Otter, A., Zuo, J., and Moss, P. (2022). Extended interval BNT162b2 vaccination enhances
peak antibody generation. npj Vaccines 7, 14.

Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
Faustini, S., Al-Taei, S., Moore, S.C., *et al.* (2021a). Immunogenicity of standard and
extended dosing intervals of BNT162b2 mRNA vaccine. Cell *184*, 5699-5714.e5611.

Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
Faustini, S., Al-Taei, S., Moore, S.C., *et al.* (2021b). Immunogenicity of standard and
extended dosing intervals of BNT162b2 mRNA vaccine. Cell *184*, 5699-5714.e5611.

- 1230 Reynolds, C.J., Pade, C., Gibbons, J.M., Otter, A.D., Lin, K.-M., Muñoz Sandoval, D.,
- 1231 Pieper, F.P., Butler, D.K., Liu, S., Joy, G., et al. (2022). Immune boosting by B.1.1.529
- 1232 (Omicron) depends on previous SARS-CoV-2 exposure. Science.

- Rosenberg, E.S., Dorabawila, V., Easton, D., Bauer, U.E., Kumar, J., Hoen, R., Hoefer, D.,
 Wu, M., Lutterloh, E., Conroy, M.B., *et al.* (2021). Covid-19 Vaccine Effectiveness in New
 York State. New England Journal of Medicine *386*, 116-127.
- Rydyznski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D.,
 Belanger, S., Abbott, R.K., Kim, C., Choi, J., *et al.* (2020). Antigen-Specific Adaptive
 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
 Severity. Cell *183*, 996-1012.e1019.
- Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z.,
 Gaebler, C., Caskey, M., Nussenzweig, M.C., *et al.* (2021). Plasma Neutralization of the
 SARS-CoV-2 Omicron Variant. New England Journal of Medicine *386*, 599-601.
- Scurr, M.J., Lippiatt, G., Capitani, L., Bentley, K., Lauder, S.N., Smart, K., Somerville, M.S.,
 Rees, T., Stanton, R.J., Gallimore, A., *et al.* (2022). Magnitude of venous or capillary bloodderived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature
 Communications *13*.
- 1247 Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. Cell *184*, 1248 861-880.
- Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele,
 S., Adland, E., Brown, H., Chinnakannan, S., *et al.* (2021). Two doses of SARS-CoV-2
 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
 Nature Communications *12*, 5061.
- Skowronski, D.M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot,
 D., Prystajecky, N., Tyson, J.R., Gilca, R., *et al.* (2022). Two-dose SARS-CoV-2 vaccine
 effectiveness with mixed schedules and extended dosing intervals: test-negative design
 studies from British Columbia and Quebec, Canada. Clinical Infectious Diseases, ciac290.
- Ssemaganda, A., Nguyen, H.M., Nuhu, F., Jahan, N., Card, C.M., Kiazyk, S., Severini, G.,
 Keynan, Y., Su, R.-C., Ji, H., *et al.* (2022). Expansion of cytotoxic tissue-resident CD8+ T
 cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19
 vaccination. Nature Communications *13*.
- Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,
 Gibbons, J.M., Le Bert, N., Tan, A.T., *et al.* (2022). Pre-existing polymerase-specific T cells
 expand in abortive seronegative SARS-CoV-2. Nature *601*, 110-117.
- Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin,
 B., Phillips, E., Mallal, S., *et al.* (2022). SARS-CoV-2 vaccination induces immunological T
 cell memory able to cross-recognize variants from Alpha to Omicron. Cell *185*, 847859.e811.
- Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N.,
 Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., *et al.* (2021). Effectiveness of mRNA
 BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the
 USA: a retrospective cohort study. The Lancet *398*, 1407-1416.
- 1272 Tartof, S.Y., Slezak, J.M., Puzniak, L., Hong, V., Xie, F., Ackerson, B.K., Valluri, S.R., Jodar,
 1273 L., and McLaughlin, J.M. (2022). Durability of BNT162b2 vaccine against hospital and
 1274 emergency department admissions due to the omicron and delta variants in a large health
 1275 system in the USA: a test-negative case–control study. The Lancet Respiratory
 1276 Medicine.

- 1277 Tomic, A., Skelly, D.T., Ogbe, A., O'Connor, D., Pace, M., Adland, E., Alexander, F., Ali, M.,
- 1278 Allott, K., Azim Ansari, M., et al. (2022). Divergent trajectories of antiviral memory after
- 1279 SARS-CoV-2 infection. Nature Communications 13, 1251.
- 1280 UK Health Security Agency (2022). COVID-19 vaccine surveillance report: 12 May 20221281 (week 19).
- Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Adams, L.,
 Hobson, P., Hatipoglu, E., *et al.* (2021). AZD1222-induced neutralising antibody activity
 against SARS-CoV-2 Delta VOC. The Lancet *398*, 207-209.
- Ward, H., Whitaker, M., Flower, B., Tang, S.N., Atchison, C., Darzi, A., Donnelly, C.A., Cann,
 A., Diggle, P.J., Ashby, D., *et al.* (2022). Population antibody responses following COVID-19
 vaccination in 212,102 individuals. Nature Communications *13*, 907.
- Wei, J., Matthews, P.C., Stoesser, N., Newton, J.N., Diamond, I., Studley, R., Taylor, N.,
 Bell, J.I., Farrar, J., Kolenchery, J., *et al.* (2022a). Correlates of protection against SARSCoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or
 breakthrough infection in the UK general population. medRxiv, 2022.2011.2029.22282916.
- Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E.,
 Cook, D., Bell, J.I., Newton, J.N., *et al.* (2022b). Antibody responses and correlates of
 protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
 Nature Medicine *28*, 1072-1082.
- Whitaker, H.J., Gower, C., Otter, A.D., Simmons, R., Kirsebom, F., Letley, L., Quinot, C.,
 Ireland, G., Linley, E., Ribeiro, S., *et al.* (2021). Nucleocapsid antibody positivity as a marker
 of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant,
 vaccination, and choice of assay cut-off. medRxiv, 2021.2010.2025.21264964.
- Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G.,
 Hayes, A., Henry, L., Hester, J., *et al.* (2019). Welcome to the Tidyverse. Journal of Open
 Source Software *4*, 1686.
- 1303 Zhang, Z., Mateus, J., Coelho, C.H., Dan, J.M., Moderbacher, C.R., Gálvez, R.I., Cortes,
- 1304 F.H., Grifoni, A., Tarke, A., Chang, J., *et al.* (2022). Humoral and cellular immune memory to 1305 four COVID-19 vaccines. Cell .
- 1306
- 1307

It is made available under a CC-BY-NC-ND 4.0 International license .

1308

					P ^e
	All	AZ	Pfizer Short	Pfizer Long	value
Total N	684	92	84	508	
Dosing Intervals					
Median Days	71	74	24	71	
Median Weeks	10	11	3	10	
Interquartile Range (Days)	63-77	64.75-78	21-27	66-78	
Maximum Days	158	158	38	120	
Minimum Days	14	53	0	0	
Range (Days)	14-158	53:158	0:38	0:120	
Infection Status					
		45		248	
		(51.1%)[0.01	49	(52.4%)[0.18	
Naïve, N (%)	342 (50.0%)]	(41.7%)[1.3]]	
		47	35	266	
Total Previous SARS-CoV-2,		(48.9%)[0.01	(58.3%)[1.28	(48.8%)[0.18	
N (%)	342 (50.0%)				0.22
Previous infection at	200	20	20	200	
baseline, N°	269	39	30	200	
PCR+ Breakthrough	22	F	4	24	
Serecenverted During		5	4	24	
Study N ^c	19	6	1	12	
	45			42	
	77	77	71	71	
	22	22	22	22	
Age Bange	22	22	22	22-71	
Median Age In Years	13	13	15	/3	
Interguartile Range Age	33-523	27-56	37-55	33-51 25	
	33-32,3	27-30	57-55	55-51.25	
		68	50	387	
		(73.9%)[0.00	(59 5%)[2 33	(76.2%)[0.38	
Female. N (%)	505 (73,8%)]]]	
		24		121	
		(26.1%)[0.00	34 (40.5%)	(23.8%)[1.07	0.00
Male, N (%)	179 (26.2%)		[6.57]		6
Ethnicity					
White, N (%) ^d	464 (83.8%)	71 (79.8%)	56 (84.8%)	337 (84.5%)	
Asian, N (%) ^d	56 (10.1%)	12 (13.5%	5 (7.6%)	39 (9.8%)	
Black, N (%) ^d	7 (1.3%)	0 (0.0%)	1 (1.5%)	6 (1.5%)	
Other, N (%) ^d	27 (4.9%)	6 (6.7%)	4 (6.1%)	17 (4.3%)	
Unreported, N	130	3	18	109	

1309

^aPrevious infection at baseline (time of 1st vaccination) = previous PCR+ SARS-CoV-2 +/- anti-nucleocapsid

1311 IgG positive at baseline

1312 ^bPCR+ Breakthrough infections include 9 re-infections who were in the "Previous infection at baseline" group

It is made available under a CC-BY-NC-ND 4.0 International license .

- 1313 ^cSeroconverted during study = No documented PCR+, lateral flow test or suspected SARS-CoV-2 infection,
- 1314 but asymptomatic rise in anti-nucleocapsid IgG (MSD) above assay positivity threshold and > 2x baseline
- 1315 ^dPercentage of reported ethnicities
- 1316 ^eDifferences between the groups were assessed using the Chi squared test.

1317

- 1318 Table 1. Demographic characteristics of participants in the study
- 1319

It is made available under a CC-BY-NC-ND 4.0 International license .

1320 FIGURES AND FIGURE LEGENDS

1321



1322 1323 **Fig**

Figure 1. Study Design

- 1324 Schematic representation of vaccination and phlebotomy time points.
- 1325 Figure created using Biorender.
- 1326

1327

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure 2. Comparison of T cell and IgG responses six months after the second
 dose of vaccine according to vaccine regime and infection status.

1331 (A) Comparison of IFNγ ELISpot responses to spike (S, ancestral strain) from

1332 cryopreserved peripheral blood mononuclear cells (PBMCs) in naïve (grey circles) 1333 participants 6 months after 2 doses of BNT162b2 (Pfizer-BioNTech) delivered with a 1334 short dosing interval ("Short", 3-5 weeks, n=33), or a long dosing interval ("Long", 6-1335 17 weeks, n=116), or 6 months after 2 doses of AZD1222 (AstraZeneca) vaccine 1336 ("AZ", n=29); or previously infected (closed red circles infected at baseline, open red 1337 circles infected during study) BNT162b2 short (n=13), previously infected BNT162b2 long (n=94), and AZ (n=16) vaccinated individuals. (B) Effect of vaccine regimen and 1338 infection status on SARS-CoV-2 S-specific IgG responses in naïve short (n=38), long 1339 1340 (n=170), and AZ (n=39); and previously infected short (n=18), long (n=99), and AZ

It is made available under a CC-BY-NC-ND 4.0 International license .

1341 (n=28) vaccinated individuals. (C) Effect of vaccine regime and infection status on 1342 SARS-CoV-2 RBD-specific laG responses in naïve short (n=38), long (n=169), and AZ (n=37); and previously infected short (n=18), long (n=99), and AZ (n=28) 1343 1344 vaccinated individuals. (D) Association of membrane (M) and nucleocapsid (N) 1345 protein specific T cell and SARS-CoV-2 N-specific IgG responses in participants 6 months after second dose, and 28 days after third dose (hence participants can have 1346 >1 value), by infection status. ELISpot values are expressed as spot forming units 1347 per million (SFU/10⁶) PBMCs. Data displayed are responses to peptide pools 1348 representing the sum of S1 and S2 units of S (ancestral strain). IgG responses were 1349 1350 measured in serum 6 months after the second dose using multiplexed MSD 1351 immunoassays and are shown in arbitrary units (AU)/mL. Bars represent the median. 1352 Vaccine regimes and infection status were compared with Kruskal-Wallis and Dunn's 1353 multiple comparisons test (A-C) and Spearman's tests (D), with 2-tailed p-values 1354 shown above linking lines. Where p-values are absent, comparison was not 1355 statistically significant (p>0.05). Dashed lines in (D) represent thresholds for a positive response: SARS-CoV-2 N IgG - based on the mean concentrations 1356 measured in 103 pre-pandemic sera + 3 Standard Deviations (3874 AU/mI); SARS-1357 1358 CoV-2 M & N IFNy ELISpot assay – mean + 2 Standard Deviations of the DMSO wells across all experiments in the study $(33 \text{ SFU}/10^6)$. 1359 1360



1361

1362Figure 3. Time course of T cell, binding IgG and B cell responses for all1363participants, and cross section of responses one month post dose 3 after 21364doses of BNT162b2 (short or long interval) or AZD1222 vaccine.

(A) Time course comparison of T cell responses to SARS-CoV-2 spike by IFNγ
 ELISpot assay for all vaccine regimens up to 6 months post third dose (n=613). (B)

It is made available under a CC-BY-NC-ND 4.0 International license .

1367 Time course comparison of IgG antibody response to SARS-CoV-2 spike by 1368 MesoScale Discovery assay for all vaccine regimens up to 6 months post third dose (n=680). (C) Time course comparison of B cell responses to SARS-CoV-2 spike by B 1369 1370 cell ELISpot assay for all vaccine regimens up to one month post third dose. (D) 1371 Comparison of T cell responses one month after the third booster dose by primary vaccine regimen (BNT162b2 Short, Long or AZD1222). (E) Comparison of IgG 1372 antibody responses one month after the third booster dose by primary vaccine 1373 regimen. (F) Comparison of B cell responses one month after the third booster dose 1374 by primary vaccine regimen. Grey circles = naïve individuals, red circles = hybrid 1375 1376 immunity. Bars represent the median. Comparisons within groups were tested with 1377 the Kruskal-Wallis nonparametric test and Dunn's multiple comparisons correction, with 2-tailed p values shown above linking lines for significant differences with 1378 p≤0.05. Unpaired comparisons between naïve and hybrid immune time points were 1379 1380 tested with the Mann Whitney test.

1381 1382

1383

1384

1385

It is made available under a CC-BY-NC-ND 4.0 International license .





Cryopreserved PBMCs from a subset of 95 participants who received BNT162b2 1390 (Pfizer/BioNTech) with a short or long dosing interval, or AZD1222 (AstraZeneca), 1391 1392 one month after the second dose, were analysed by intracellular cytokine staining 1393 and flow cytometry. The individual cytokine expression levels of total IFNy, IL2 or 1394 TNF are shown as a percentage of (A) the CD4⁺ T cell population (top panels), or (B) 1395 the CD8⁺ T cell population (bottom panels). Populations were analysed by gating on 1396 single, live, CD3⁺ cells (Supplementary figure 1). Short = BNT162b2 short interval; 1397 Long = BNT162b2 long interval; AZ = AZD1222. Naïve participants are shown as 1398 grey circles and hybrid immunity group are red circles. Box plots represent the median, IQR and whiskers 1.5 x the IQR. (C) The T cell populations responsible for 1399 1400 IFNy or IL2 expression were assessed as the proportion of IFNy or IL2 expressed

It is made available under a CC-BY-NC-ND 4.0 International license .

1401 by CD4⁺ T cells, calculated by dividing the cytokine production in CD4⁺ T cells by the total cytokine production in response to spike in both CD4⁺ and CD8⁺ T cells. (D) 1402 1403 Polyfunctionality was evaluated by combined expression of IFNy, IL2 and TNF in 1404 CD4⁺ and CD8⁺ T cells, showing the percentage of cells making all three cytokines. 1405 Naïve short: n=20, Naïve long: n=15, Naïve AZ n=14, Hybrid immunity short: n=13, Hybrid immunity long: n=17, Hybrid immunity AZ: n= 16. Unpaired comparisons 1406 across two groups were performed using the Mann Whitney test with 2-tailed p 1407 values shown above linking lines when 2-tailed p≤0.05. 1408 1409

It is made available under a CC-BY-NC-ND 4.0 International license .



1410

Figure 5. T cell proliferation to SARS-CoV2 at 6 months after the primary vaccine course of 2 doses of BNT162b2 or AZD1222

T cell proliferation to SARS-CoV2 peptide pools was assessed by flow cytometry in 1413 PBMC from 73 participants who had received either BNT162b2 with a short or long 1414 1415 vaccine dosing interval or AZD1222 vaccine and were either naïve or were previously infected (either at baseline or during the course of the study). (A) Relative 1416 frequency of CD4⁺ and CD8⁺ T cells proliferating to individual peptide pools spike 1417 S1, spike S2, membrane (M) and nucleocapsid (N) protein in naïve (n=39) and 1418 hybrid immunity (n=34) individuals. Grey colour=missing value. (B, D) Proliferation to 1419 S1 and S2 and (C, E) M and N protein in CD4⁺ (B, C) and CD8⁺ (D, E) T cells are 1420 shown across the 3 vaccine regimens separated by exposure status (naïve versus 1421 hybrid immunity). Individual data points and median with IQR are displayed for naïve 1422 1423 short: n=16, naïve long: n=15, naïve AZ: n=8, hybrid immunity short: n=11, hybrid 1424 immunity long: n=12, hybrid immunity AZ: n=11. Comparisons between naïve and

It is made available under a CC-BY-NC-ND 4.0 International license .

1425 hybrid immunity within each vaccine regimen were performed using the Mann 1426 Whitney test, and comparisons between the three vaccine regimens within the naïve 1427 and previously infected groups was performed using the Kruskal Wallis test and 1428 Dunn's multiple comparisons correction. 2-tailed P values are shown only for 1429 statistically significant comparisons ($p \le 0.05$). Fold change between medians of two groups are shown in brackets next to or under p value. (Fold change is not shown for 1430 1431 those comparisons where there was no proliferation detected in one of the groups.) Grey circles = naïve individuals, red circles = participants with hybrid immunity. 1432 1433

It is made available under a CC-BY-NC-ND 4.0 International license .









C Neutralizing antibody titers V3 + 1 month







E Timecourse of neutralizing antibody titers



1436

Figure 6. Neutralizing antibody and ACE2 inhibition titre profiles against SARSCoV-2 variants of concern 6 months after 2 doses of BNT162b2 or AZD1222
and one month after a third vaccine with BNT162b2.

Focus Reduction Neutralization Assay 50% (FRNT₅₀) antibody titres against the
Victoria isolate (orange), delta (B.1.617.2, purple) and omicron BA.1 (B.1.1.529
BA.1, blue) taken from infection-naïve participants. FRNT₅₀ is the reciprocal dilution

1443 of the concentration of serum required to produce a 50% reduction in infectious

- 1444 focus forming units of virus in Vero cells (ATCC CCL-81). Participants either
- 1445 received 2 doses of BNT162b2 (Pfizer-BioNTech) vaccine delivered in a short
- 1446 ("Short", 3-5 weeks, n=20) or long ("Long", 6-17 weeks, n=20) dosing interval, or 2
- 1447 doses of AZD1222 (AstraZeneca) vaccine ("AZ", n=16). Neutralizing antibody titres
- 1448 are shown in (A) 6 months after the second dose, and (C) for the same individuals,
- 1449 one month after a third "booster" dose of mRNA vaccine for all participants.
- 1450 Geometric mean neutralizing titres with 95% confidence intervals are shown. (E)
- 1451 Comparison of the data from (A) and (C), plotted as means with error bars by
- 1452 vaccine regimen 6 months after the second vaccine (V2+ 6 months), one month after

It is made available under a CC-BY-NC-ND 4.0 International license .

1453 the third "booster" mRNA vaccine (V3+1 month). The range of fold change (median) 1454 between V2+6 months and V3+1 month for the three vaccine regimens (Short – dashed line, Long – solid line, and AZ – dotted line) is shown in brackets for each 1455 1456 variant. Data in panels (A), (C) and (E) from the Short group (n=20) has been 1457 previously published (Deinirattisai, Huo et al. 2022). (B) Impact of Short or Long BNT162b2 vaccine dosing interval and AZ on the ability of sera to inhibit ACE2 1458 binding to SARS-CoV-2 spike (Victoria isolate, delta (B.1.617.2), Omicron BA.1 1459 (B.1.1.529 BA.1), alpha (B.1.1.7), beta (B.1.351) and gamma (P.1) 6 months after 1460 the second dose and (D) one month after a third "booster" dose with mRNA vaccine. 1461 1462 ACE2 inhibition was analysed using a multiplexed MSD® assay and performed at a serum dilution of 1:10 at V2 + 6 months and 1:100 at V3+1 months. Data are shown 1463 as percentage of inhibition. Bars represent the median with 95% confidence 1464 intervals. Naïve, Short: n=20; Naïve, Long: n=20; Naïve, AZ: n=16 for V2+6 months; 1465 1466 Naïve, Short: n=19; Naïve, Long: n=20; Naïve, AZ: n=10 for V3+1 month. Vaccine regimens were compared with the Kruskal-Wallis nonparametric test and Dunn's 1467 multiple comparisons correction, with 2-tailed p values shown above linking lines 1468 when 2-tailed p≤0.05, and fold changes are shown between the columns. 1469 1470 1471 1472

1473

It is made available under a CC-BY-NC-ND 4.0 International license .



1474

Figure 7. Antibody responses to omicron subvariants up to 6 months post 1475 dose 3. IgG binding measured on the MSD platform to spike from ancestral SARS-1476 1477 CoV-2 (orange) and the BA.1 (blue), BA.2 (grey), BA.3 (brown), BA.3 (maroon), BA.5 (green) omicron variants at 6 months after two doses of BNT162b2 (A) and one 1478 month post dose 3 of BNT162b2 vaccine in infection naïve participants (n = 21) (B) 1479 and 6 months post dose 3 of BNT162b2 vaccine (C) in both infection naïve 1480 participants (n=60) and in participants who became infected with an Omicron variant 1481 between 1 and 6 months post dose 3 (n=55). ACE2 inhibition by plasma from the 1482

It is made available under a CC-BY-NC-ND 4.0 International license .

1483 same donors in A-C at 6 months post dose 2 (D), one month post dose 3 (E) and 6 1484 months post dose 3 (F) ACE2 inhibition was performed at a serum dilution of 1 in 100 to account for saturation of the assay, as seen in figure 6. Comparisons between 1485 1486 responses to ancestral and Omicron variants were made using Friedman's test, with 1487 2-tailed p-values of significant differences ($p \le 0.05$) shown above linking line. (G) 1488 Neutralising antibody was measured at one month post dose 3 and 6 months post dose 3 by focus reduction neutralisation titre 50% (FRNT₅₀) for Victoria strain 1489 (orange), BA.1 (blue), BA.2 (grey) and BA.5 (green) omicron variants in participants 1490 who remained infection naïve (n=33) and those who became infected in between 1491 1492 one and 6 months post dose 3 (n=11). Filled circles indicate participants who remain 1493 infection naïve, participants who became infected with an omicron variant between one month and 6 months after the third vaccine dose are indicated in unfilled circles. 1494 1495 Paired comparisons between one and 6 months post vaccine were tested using the 1496 Wilcoxon signed rank test, and comparis'n's between groups were tested using the 1497 Mann Whitney test. 1498

1499

It is made available under a CC-BY-NC-ND 4.0 International license .



T cell responses to Omicron

Figure 8. Comparison of cytokine response at 6 months post dose 2 against ancestral strain and omicron BA.1 variant according to infection status. Longitudinal comparison of T cell and B cell responses against ancestral strain and omicron BA.1 variant according to vaccine regimen and infection status.

(A) Comparison of percentage IFNy, TNF and IL2 positive CD4 T cells against 1506 ancestral strain and omicron BA.1 variant by intracellular cytokine staining of 1507 cryopreserved peripheral mononuclear cells (PBMCs) in either infection naive 1508 participants or participants with hybrid immunity. (B) Comparison of percentage 1509 1510 IFNy, TNF and IL2 positive CD8 T cells against ancestral strain and omicron BA.1 1511 variant by intracellular cytokine staining of PBMCs in either infection naïve participants or participants with hybrid immunity. Pairwise comparison of T cell 1512 1513 responses to spike from ancestral strain and omicron BA.1 variant from PBMCs by 1514 IFNy ELISpot assay (C) in participants 6 months post primary vaccine course (2) doses of BNT162b2 or AstraZeneca), n=215, and (D) one month post third 1515 BNT162b2 vaccine dose, n=175. Displayed are responses to peptide pools 1516 representing the sum of S1 and S2 units of S from ancestral strain and omicron 1517 1518 variant. (E) Pairwise comparison of IFNy ELISpot responses in a subset of 1519 participants (n=36) to only the 51 out of 178 peptides spanning spike that have 1520 mutations in omicron BA.1 compared to the ancestral strain. (F) T cell responses to 1521 spike from ancestral strain and omicron BA.1, BA.2 and BA.4/5 variants in PBMCs from naïve (n=28) and hybrid immune (n=46) donors by IFNy ELISpot assay. (G) 1522 1523 Pairwise comparison of B cell responses to S in ancestral strain and omicron BA.1 variant from PBMCs in participants one month post vaccine dose 2 (n=12); (H) 6 1524 1525 months post second vaccine dose (n=43); (I) one month post third vaccine dose 1526 (n=80). Orange circles = responses against Victoria variant; blue circles = responses 1527 against omicron BA.1 variant. Displayed are responses to peptide pools representing 1528 S1 and S2 units of S from ancestral and omicron variants. ELISpot values are expressed as antibody SFU/10⁶ PBMCs. Horizontal lines represent median values. 1529 Comparisons between responses to ancestral and Omicron variants were made 1530 1531 using Wilcoxon matched-pairs signed rank test, with 2-tailed p-values of significant 1532 differences (p≤0.05) shown above linking line.

SUPPLEMENTARY INFORMATION

Supplementary Table 2. Antibodies used for intracellular cytokine staining and proliferation

Marker name	Fluorochrome	Clone	Species reactivity	Host species	Isotype	Manufacturer	Catalogue number	Dilution used
CD3	PerCP	UCHT1	human	mouse	lgG1 κ	Biolegend	300428	100
CD3	FITC	UCI IT1	human	mouse	lgG1, κ	Biolegend	300440	50
CD4	APC	RPA-T4	human	mouse	lgG1, ĸ	Biolegend	300514	200
CD8	PE-Cy7	RPA-T8	human	mouse	lgG1, κ	Biolegend	301012	200
CD8	BV510	RPA-T8	human	mouse	lgG1, κ	Biolegend	301048	600
CD14	APC-Fire750	M5E2	human	mouse	lgG2a, ĸ	Biolegend	301854	200
IFN-γ	PE	4S.B3	human	mouse	lgG1, κ	Biolegend	502508	50
TNF	FITC	MAb11	human	mouse	lyG1, ĸ	Biolegend	502906	40
IL-2	PE-Cy7	MQ1-17H12	human	rat	lgG2a, ĸ	eBioscience	25-7029-41	100

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S1. Gating strategy for T cell cytokine secretion (ICS) and proliferation (A) For ICS assays single cells were gated using forward scatter (FSC)- area (A) and FSC- height (H) followed by a lymphocyte gate using FSC-A and side scatter (SSC)-A. Live CD3⁺ T cells were gated based on exclusion of dead cells (LD-NiR) and monocytes (CD14 APC Fire-750) as well as positivity for CD3 PerCP. T cell subsets were identified based on staining for CD4 APC and CD8 BV510 respectively and

It is made available under a CC-BY-NC-ND 4.0 International license .

expression of cytokines (IFNγ, TNF, IL-2) was then identified in the CD4⁺CD8⁻ gate as well as the CD8⁺CD4⁻ gate. Representative gating is shown for the DMSO negative control and the PMA/Ionomycin positive control. In the case of PMA/Ionomycin the CD4⁺ gate was extended all the way to the CD4⁻ population due to downregulation of expression upon treatment (not shown in the figure). (B) For proliferation assays, lymphocytes were gated FSC-A and SSC-A parameters, followed by two subsequent single cell gates on FSC-H and width (W) as well as SSC-H and W to exclude doublets. From there live T cells were gated (LD-NiR low CD3⁺) and T cell subsets were identified (CD4⁺CD8⁻ and CD8⁺CD4⁻) using CD4⁺ APC and CD8⁺ PE-Cy7. Within the CD4⁺ and the CD8⁺ T cell gate proliferating cells were identified by gating on cells with reduced CTV (CellTrace[™] Violet) fluorescence intensity.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S2. Comparison of T cell and IgG responses in those previously infected at baseline, infected during study, or infected at any time, at six months post second vaccine.

(A) Comparison of IFNy ELISpot responses to S (ancestral strain) from cryopreserved PBMCs in short naïve (n=33), infected during study (n=2), previously infected at baseline (n=11) individuals; long naïve (n=116), infected during study (n=32), previously infected at baseline (n=62) individuals; AZ naïve (n=29), infected during study (n=6), previously infected at baseline (n=10) individuals. (B) Effect of vaccine regime and infection status on SARS-CoV-2 S-specific IgG responses in short naïve (n=38), infected during study (n=2), previously infected at baseline (n=21); long naïve (n=132), infected during study (n=36), previously infected at baseline (n=96); AZ naïve (n=27), infected during study (n=7), previously infected at baseline (n=23). Grey circles = naïve; solid red circles = previous infection at baseline; open red circles = infected during study. ELISpot values are expressed as SFU/10⁶ PBMCs, with values displayed responses to peptide pools representing S1 and S2 units of S (ancestral strain). IgG responses were measured in serum 6 months after the second dose using multiplexed MSD immunoassays and are shown in arbitrary units (AU)/mL. Horizontal bars represent the median. Vaccine regimens and vaccine status was compared using the Kruskal-Wallis test and Dunn's multiple

A T calls: SARS-CoV-2 Spike at V2 + 6 months

It is made available under a CC-BY-NC-ND 4.0 International license .

comparisons correction, with 2-tailed p-values shown above linking lines where significant ($p \le 0.05$). ns = not significant.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S3. Time course of T cell, binding IgG and B cell responses 1 and 6 months after 2 doses of BNT162b2 (short or long interval) or AZD1222 vaccine: Responses are shown one and 6 months after 2 doses and following a third dose of BNT162b2 for (A) T cell responses to SARS-CoV-2 spike by IFNy ELISpot assay after BNT162b2 (Pfizer-BioNTech) delivered with a short dosing interval ("Short", 3-5 weeks, n=11-44 naïve, n=10-24 hybrid immunity), (B) IgG responses to SARS-CoV-2 spike by MesoScale Discovery (MSD) assay after BNT162b2 Short (n=24-59 naïve, n=8-24 hybrid immunity) and (C) B cell responses to SARS-CoV-2 spike by B cell Elispot assay after BNT162b2 Short (n=6-13 naïve, n=1-4 hybrid immunity). Responses are shown 1 and 6 months after 2 doses and following a third dose of BNT162b2 for (D) T cell responses to spike after a long interval ("Long", 6-17 weeks, n=49-189 naïve, n=31-156 hybrid immunity), (E) IgG responses to spike by MSD assay after BNT162b2 Long (n=123-178 naïve, 78-203 hybrid immunity) and (F) B cell responses to spike after BNT162b2 Long (n=12-47 naïve, n=22-39 hybrid immunity). Responses are shown 1 and 6 months after 2 doses and following a third dose of BNT162b2 for (G) T cell responses to spike after AZD1222 (AstraZeneca) vaccine ("AZ", n=18-26 naïve, 6-26 hybrid immunity), (H) IgG responses to spike by

It is made available under a CC-BY-NC-ND 4.0 International license .

MSD assay after AZD1222 (n=28-54 naïve, n=16-44 hybrid immunity) and (I) B cell responses to spike after AZD1222 (n=5-8 naïve, n=7-10 hybrid immunity).



Figure S4. T cell and IgG Antibody responses to membrane protein, nucleocapsid protein and receptor binding domain.

It is made available under a CC-BY-NC-ND 4.0 International license .

T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of BNT162b2 short dosing interval. (A) IFNy ELISpot responses in PBMCs, (B) IgG against receptor binding domain (RBD) and (B) IgG against nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of BNT162b2 long dosing interval. (D) IFNy ELISpot responses in PBMCs, (E) IgG against receptor binding domain (RBD) and (F) IgG against nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N). T cell and IgG antibody responses to membrane (M) and nucleocapsid (N) protein in participants receiving a primary course of AstraZeneca. (G) IFNy ELISpot responses in PBMCs, (H) IgG against receptor binding domain (RBD) and (I) IgG against nucleocapsid (N). Grey circles = naïve individuals, red circles = hybrid immunity. Bars represent the median. Comparisons are with the Kruskal-Wallis nonparametric test and Dunn's multiple comparisons correction, with 2-tailed p values shown above linking lines for significant differences with $p \le 0.05$.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S5. Correlation between ACE2 inhibition and neutralising antibodies. Correlation between the percentage of ACE2 inhibition and neutralisation titres against (A) Victoria, (B) Delta (B.1.617.2) and (C) Omicron BA.1 (B.1.1.529 BA.1), expressed as Focus Reduction Neutralization Assay 50% (FRNT₅₀), determined in infection-naïve participants after receiving two doses of BNT162b2 (Pfizer-BioNTech) vaccine delivered in a short ("Short", 3-5 weeks, n=20) or long ("Long", 6-14 weeks, n=20) dosing interval, or two doses of AZD1222 (AstraZeneca) vaccine ("AZ", n=15) 6 months after the second dose. Correlation between the percentage of ACE2 inhibition and neutralisation titres against (D) Ancestral, (E) Omicron BA.1 and (F) Omicron BA.2 expressed as half maximal inhibitory concentration (IC50), determined in infection-naïve participants one month after third vaccine dose. Correlation between the percentage of ACE2 inhibition and neutralisation titres against (G) Ancestral, (H) Omicron BA.1 and (I) Omicron BA.2 expressed as IC50, determined in infection-naïve participants 6 months after third vaccine dose. Pairwise correlations were assessed using Spearman's rank-order correlation. Rhombus = Pfizer short, triangle= Pfizer Long, circle=AZ.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure S6. T cell cytokine responses and proliferation to the omicron (BA.1) variant 6 months after the primary vaccine course with BNT162b2 or AZD1222. (A) Combined data from naïve (grey) and hybrid immunity (red) participants shows cytokine responses (IFN-γ and IL-2) in CD4+ T cells at 6 months post second dose of either BNT162b2 (short and long dosing interval) or AZD1222. Proliferative responses of CD4⁺ and CD8⁺ T cells to SARS-CoV2 spike (S1+S2) from the ancestral strain were compared to the omicron BA.1 variant in a subset of (B, D) naïve (n=9) and (C, E) hybrid immunity (hybrid immunity, n=27) participants from all three vaccine regimens 6 months after the second dose. Individual data points are presented, and paired values are connected with a line. Paired testing was performed using Wilcoxon signed rank test and 2-tailed p values for significant differences (p≤0.05) are displayed. Closed circles = ancestral spike, open circles = omicron BA.1 spike, Grey = naïve individuals, red= individuals with hybrid immunity.